



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Association of Microalbuminuria and High-normal 24-hour Urinary Albumin Excretion with Metabolic Syndrome in the General Chinese Population

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031443
Article Type:	Research
Date Submitted by the Author:	04-May-2019
Complete List of Authors:	Xu, Jianwei; National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Ma, Jixiang; Chinese Center for Disease Control and Prevention Chen, Xiaorong; National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention Yan, Liuxia; National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention Cai, Xiaoning; National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention Guo, Xiaolei; Shandong Center for Disease Control and Prevention Zhang, Yongqing; Jiangsu Center for Disease Control and Prevention Wu, Jing; National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention
Keywords:	Metabolic Syndrome, Microalbuminuria, Urinary Albumin

SCHOLARONE™  
Manuscripts



## Abstract

**Objective:** Microalbuminuria has been described as a risk factor for metabolic syndrome (MetS). However, the association between MetS components with microalbuminuria and 24-h urinary albumin excretion (UAE) has not been clearly explained in the general Chinese population. We aimed to analyze the association between microalbuminuria and high-normal 24-h UAE with MetS and its components.

**Design:** Cross-sectional observational study.

**Setting:** Four selected counties/districts in China's Shandong and Jiangsu Provinces.

**Participants:** A total of 2261 participants aged 18-69 years were included in this study. Participants with missing data on physical examination or incomplete urine collection are not included in the analysis.

**Results:** The prevalence of microalbuminuria was 9.0%, and the mean 24-h UAE was 18.0 mg/d. The prevalence of microalbuminuria was significantly higher for the MetS, high blood pressure, high triglycerides, low high-density lipoprotein cholesterol (HDL-C) and hyperglycemia groups, but not for central obesity. Both microalbuminuria and mean 24-h UAE were significantly increased with a number of MetS components. The adjusted odds ratio (OR) and 95% confidence interval (CI) for MetS with microalbuminuria was 2.95 (2.15-4.04) compared to those without microalbuminuria. Microalbuminuria patients were significantly associated with three components of MetS: high blood pressure, high triglycerides and hyperglycemia with OR=1.86, 95% CI 1.31-2.64; OR=1.80, 95% CI 1.31-2.46; and OR=1.84, 95% CI 1.34-2.53, respectively. No significant association of microalbuminuria and central obesity, low HDL-C was found. The presence of MetS were gradually elevated according to the normal range 24-h UAE quartiles: OR=1.00, OR=1.22, OR=1.14 and OR=2.02, respectively. Hyperglycemia was also significantly increased according to the normal range 24-h UAE quartiles.

**Conclusions:** Microalbuminuria and elevated 24-h UAE within normal range were closely associated with MetS in the Chinese population, which may provide a basis for the development of early

1  
2  
3 47 intervention to decrease the effects of MetS.  
4  
5 48 **Keywords:** Metabolic Syndrome; Microalbuminuria; Urinary Albumin  
6  
7

8 49  
9

10  
11  
12 50 **Strengths and limitations of this study**  
13

- 14  
15 51 ■ We used 24-h UAE to define microalbuminuria, which was more accurate than most previous studies.  
16  
17 52 ■ This is the largest sample size of the general Chinese population collected 24-h urine.  
18  
19 53 ■ We explore the association between high-normal 24-h UAE with MetS and its components.  
20  
21 54 ■ This causal relationship between microalbuminuria and MetS cannot be demonstrated in our cross-  
22  
23 sectional study.  
24 55  
25  
26 56

27  
28  
29 57 **INTRODUCTION**  
30

31  
32 58 Microalbuminuria (MAU), defined by abnormally high albumin excretion (30-300 mg/d) in a 24-h urine  
33  
34 59 sample, was significantly associated with chronic kidney disease, cardiovascular disease and progression  
35  
36 60 of end-stage renal disease independent of traditional risk factors [1-4]. Prospective and epidemiologic  
37  
38 61 studies have found that MAU is also a powerful predictor of all-cause and cardiovascular mortality in  
39  
40 62 the general population [5-6].  
41  
42

43 63 Metabolic syndrome (MetS) is a widely accepted description of a cluster of metabolic abnormalities  
44  
45 64 characterized by obesity, hypertension, dyslipidemia and hyperglycemia [7]. Some studies have  
46  
47 65 evaluated the relationship between MetS and MAU as a marker for early-stage chronic kidney disease  
48  
49 66 [8-11]. Significant associations between MetS and MAU have been demonstrated in the Japanese, [9]  
50  
51 67 Korean [10, 12], and Chinese populations [13-16]. However, data concerning the relationship between  
52  
53 68 individual MetS components and MAU were inconsistent, and a causal relationship between MAU and  
54  
55  
56  
57  
58  
59  
60

MetS remains unclear despite the predictive value MAU has shown in the aforementioned studies. Furthermore, the study of the association between normal range 24-h urinary albumin excretion (UAE) and MetS components has been limited [15].

The amount of 24-h UAE is considered the 'gold standard' for defining MAU [17,18]. However, most of the previous studies of MAU in the Chinese population commonly used an early morning or random spot urine sample instead of measuring 24-h UAE. Therefore, in this study, we investigated the prevalence of MAU by analyzing 24-h UAE and analyzed the association between MAU and normal range 24-h UAE with MetS and its components.

## METHODS

### Study participants

Data were derived from the supplemental baseline survey of the Shandong Ministry of Health Action on Salt Reduction and Hypertension project, which was a cross-sectional survey conducted at four sites in the Shandong and Jiangsu provinces during 2013 and 2014. A total of 9600 participants aged 18-69 years were selected by a stratified, multistage sampling method. Demographic characteristics and lifestyle information were collected during a standardized interview. Each participant underwent a physical examination. A subsample of 2408 participants collected a single 24-h urine sample. Participants with the following conditions were not required to provide urine samples: (1) patients who had difficulty collecting a urine sample; (2) patients with acute and chronic urinary infection; (3) women who were pregnant, breastfeeding, or actively menstruating; and (4) patients with severe vomiting and diarrhea. We excluded 3 subjects with missing data from their physical examination or blood samples and 127 participants with incomplete 24-h urine collection. For the purpose of the present study on microalbuminuria, we also excluded 17 subjects with macroalbuminuria, or a 24-h UAE >300 mg/d.

1  
2  
3 92 Therefore, a total of 2261 participants were included in this study.  
4  
5  
6 93 Our study was approved by the ethics committee of the National Center for Chronic and  
7  
8 94 Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention  
9  
10 95 (201311). Written informed consent was obtained from all participants.  
11

12  
13 96 **Demographic, anthropometrical and biochemical data collection**  
14

15 97 A face-to-face interview was conducted by local trained health professionals using a standard  
16  
17  
18 98 questionnaire. Relevant variables included age, sex, educational level, smoking status, alcohol intake,  
19  
20 99 regular exercise and previous diagnosis and treatment of hypertension and diabetes. During physical  
21  
22 100 examination, height, weight, waist circumference (WC) and blood pressure (BP) were measured by  
23  
24  
25 101 trained researchers using standardized protocols and techniques. Weight and height were measured with  
26  
27 102 participants dressed in light, indoor clothing without shoes by standardized techniques and calibrated  
28  
29 103 equipment. The waist circumference was measured at the narrowest point between the lower border of  
30  
31  
32 104 the rib cage and the iliac crest. The body mass index (BMI) was calculated as the weight in kilograms  
33  
34 105 divided by the height in meters squared (kg/m<sup>2</sup>). Blood pressure was measured three times by electronic  
35  
36 106 sphygmomanometer (HEM-7071, Omron Corporation, Japan), and the final blood pressure was obtained  
37  
38  
39 107 by averaging the three measurements.  
40

41 108 Fasting blood samples collected from each participant were processed and shipped in cold storage  
42  
43 109 to a certified laboratory (ADICON Clinical Laboratory Inc., Jinan, China). Fasting blood glucose (FBG),  
44  
45 110 total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) and low-density  
46  
47  
48 111 lipoprotein cholesterol (LDL-C) were measured. Plasma glucose was measured using a modified  
49  
50 112 hexokinase enzymatic method. Serum cholesterol and triglyceride levels were analyzed enzymatically  
51  
52 113 using commercially available reagents.  
53

54  
55 114 **24-h Urine collection and analysis**  
56  
57  
58

Eligible participants were instructed not to change their dietary and lifestyle habits. We provided a standard plastic container for each participant to collect a 24-h urine sample. Trained researchers gave each participant both written and verbal instructions on how to collect a 24-h urine sample. Health professionals carefully explained to the subjects the purpose of the 24-h urine collection and asked the subjects to correctly repeat the information. The exact 24-h urine collection time, including starting and ending times, was recorded by the supervising health professional. The total volume of the collection was measured by a laboratory technician, and urine aliquots were frozen at  $-20^{\circ}\text{C}$  and shipped to ADICON Clinical Laboratory in Jinan. Urinary creatinine was measured by the picric acid method. UAE was measured with an immunonephelometric method using the Olympus AU640 Analyzer, for which the coefficient of variation was 3.0%. Either a 24-h urinary volume less than 500 ml or a 24-h urinary creatinine volume that was  $\pm 2$  standard deviations (SD) outside of the sex-specific mean, 0.98 to 16.17 mmol/l for men and 0.93 to 13.60 mmol/l for women, was defined as an incomplete urine collection [19].

## Definition of the metabolic syndrome

We adopted the harmonized criteria of MetS, which defines MetS as the presence of  $\geq 3$  of the following risk factors [20]: central obesity defined as a WC  $\geq 90$  cm in men and  $\geq 80$  cm in women; high BP defined as a systolic blood pressure (SBP)  $\geq 130$  mmHg, a diastolic blood pressure (DBP)  $\geq 85$  mmHg or undergoing treatment with an antihypertensive medication; high triglycerides defined as a fasting plasma TC level  $\geq 1.7$  mmol/l or drug treatment for increased TC; low HDL-C defined as HDL-C  $< 1.0$  mmol/l in men and  $< 1.3$  mmol/l in women or drug treatment for increased HDL-C; or hyperglycemia defined as FBG level  $\geq 5.6$  mmol/l or undergoing drug treatment for increased FBG.

## Statistical analysis

Continuous variables were presented as the mean (SD), and categorical variables were presented as



percentages. According to their 24-h UAE with normal range (n=2058), study subjects were divided into four groups: Q1, 0–9.38mg/d; Q2, 9.39–11.96 mg/d; Q3, 11.97–15.46 mg/d; and Q4, 11.97–29.99 mg/d.

We performed logistic regression analyses to study the association of MAU and 24-h UAE with MetS and its components, while controlling for covariates including age, sex, education level, regular exercise, alcohol intake and smoking. Participants who were without microalbuminuria or were in the Q1 group were used as a reference group to estimate the odds ratios (ORs) and 95% confidence intervals (CIs). Tests of linear trends across increasing quartiles of 24-h UAE were conducted by treating the medians of the average 24-h UAE as a continuous variable in the logistic regression models. Statistical analyses were performed with SAS 9.3 (SAS Institute Inc.). Tests performed were two-sided, and a *p*-value <0.05 was considered statistically significant.

### Patient and public involvement

Patients and/or public were not involved in this study.

## RESULTS

### Characteristics of subjects

Among the 2261 participants, the prevalence of MAU was 9.0% (203), and prevalence was not statistically significantly different between males and females (8.8% vs. 9.1%, *p*=0.08). The mean 24-h UAE was 18.0 mg/d. The population’s characteristics were summarized according to microalbuminuria and normal range 24-h UAE quartiles in Table 1. Compared to those without MAU, participants with MAU were more likely to have higher WC, BMI, SBP and DBP, FBG and TG. Similarly, these variables were also statistically significant among increasing quartiles of 24-h UAE.

Table 1. General characteristics of the study participants

	Normal range 24-h UAE (mg/d)				<i>p</i> -value	Microalbuminuria		<i>p</i> -value
	Q1	Q2	Q3	Q4		No	Yes	
Number of subjects	515	515	516	512		2058	203	
Age (years)	41.7(13.5)	42.5(13.5)	41.8(13.5)	42.5(13.3)	0.67	42.1(13.5)	41.4(13.5)	0.48
Men (%)	51.8	48.2	50.8	48.4	0.57	49.8	48.8	0.78
BMI (kg/cm <sup>2</sup> )	24.4(3.6)	24.6(3.6)	24.7(3.9)	25.5(3.9)	<0.001	24.8(3.8)	26.0(4.5)	<0.001
WC (cm)	82.3(9.1)	82.4(9.6)	82.7(9.9)	84.8(10.5)	<0.001	83.0(9.8)	85.8(12.5)	<0.001
SBP (mmHg)	129.5(19.4)	130.7(18.5)	129.8(18.7)	133.1(20.7)	0.0111	130.8(19.4)	136.1(23.3)	<0.001
DBP (mmHg)	81.8(11.4)	83.1(10.8)	82.5(11.4)	84.9(12.2)	<0.001	83.1(11.5)	87.9(14.4)	<0.001
High-school (%)	24.1	21.9	23.1	25.4	0.61	23.6	26.6	0.34
Smoking (%)	30.1	29.1	29.1	27.3	0.80	28.9	33.0	0.22
Drinker (%)	23.7	27.6	26.2	27.3	0.47	26.2	27.1	0.78
Regular exercise (%)	17.3	16.7	22.3	22.3	0.03	19.6	30.5	<0.001
FBG (mmol/L)	5.6(1.1)	5.6(1.0)	5.7(1.1)	6.0(1.7)	<0.001	5.7(1.3)	6.5(2.4)	<0.001
TC (mmol/L)	4.7(0.9)	4.8(0.9)	4.8(0.9)	4.9(1.0)	0.0281	4.8(0.9)	5.1(1.0)	<0.001
HDL (mmol/L)	1.3(0.3)	1.3(0.3)	1.3(0.3)	1.2(0.3)	0.0203	1.3(0.3)	1.2(0.3)	0.03
LDL (mmol/L)	2.4(0.7)	2.4(0.6)	2.5(0.7)	2.5(0.7)	0.0186	2.4(0.7)	2.5(0.7)	0.06
TG (mmol/L)	1.4(1.2)	1.4(1.3)	1.5(1.4)	1.8(2.1)	<0.001	1.6(1.6)	2.3(2.4)	<0.001
Creatinine (mmol/d)	6.0(2.2)	7.4(2.6)	8.0(3.2)	8.6(3.1)	<0.001	7.5(3.0)	8.8(3.1)	<0.001
24-h UAE (mg/d)	7.7(1.2)	10.7(0.8)	13.5(1.0)	20.1(3.7)	<0.001	13.0(5.0)	68.8(50.4)	<0.001

## MAU and 24-h UAE by the number of MetS components

The prevalence of MAU in MetS and its components are shown in Table 2. The prevalence of MAU was significantly higher for the MetS, high BP, high triglycerides and hyperglycemia groups. The prevalence of MAU for subjects with 0 (n=342), 1 (n=632), 2 (n=632), 3 (n=433), and 4 or 5 (n=222) components of MetS were 5.0, 5.5, 8.2, 14.5 and 16.2%, respectively. The corresponding mean 24-h UAE measurements were 14.5, 15.1, 17.9, 22.7 and 22.8 mg/d. In aggregate, both the prevalence of MAU and the mean 24-h UAE were significantly elevated according to the number of MetS components with all *p*-values <0.001 (Fig 1).

Table 2. Association of microalbuminuria and MetS and its components

Components	Microalbuminuria (%)		<i>p</i> -value
	No (n=2058)	Yes (n=203)	
Central obesity			
No	91.49	8.51	0.1982
Yes	89.76	10.24	
High BP			
No	93.52	6.48	<0.001
Yes	88.85	11.15	
High triglycerides			
No	93.11	6.89	<0.001
Yes	86.18	13.82	
Low HDL-C			
No	91.81	8.19	0.0249
Yes	88.72	11.28	
Hyperglycemia			
No	93.94	6.06	<0.0001
Yes	87.78	12.22	
Metabolic syndrome			
No	93.52	6.48	<0.0001
Yes	84.89	15.11	

**Association between MAU and MetS components**

The association between MAU and the components of MetS are shown in Table 3. Compared with participants without microalbuminuria, the age- and gender-adjusted OR (95% CI) for MetS with microalbuminuria was 2.93 (2.15, 4.00), and the multivariate-adjusted OR (95% CI) was 2.95 (2.15, 4.04). For MetS components, both age- and gender-adjusted and multivariate-adjusted, MAU was strongly associated with high BP, high triglycerides and hyperglycemia. However, no significant association between MAU and central, obesity low HDL-C was found.

Table 3. Relationship between MAU and metabolic syndrome components

	No. of cases	without Microalbuminuria	Microalbuminuria	
			Model 1 <sup>a</sup>	Model 2 <sup>b</sup>
Metabolic syndrome	655	1.00	2.93(2.15,4.00)	2.95(2.15,4.04)
Central obesity	615	1.00	1.40(0.92,2.13)	1.02(0.65, 1.60)
High BP	1211	1.00	2.20(1.57,3.09)	1.86(1.31, 2.64)
High triglycerides	680	1.00	2.21(1.65,2.97)	1.80(1.31, 2.46)
Low HDL-C	576	1.00	1.71(1.13,2.60)	1.32(0.85, 2.04)
Hyperglycemia	1072	1.00	2.28(1.68,3.11)	1.84(1.34, 2.53)

<sup>a</sup>Model 1: adjusted for age, sex;

<sup>b</sup>Model 2: adjusted for age, sex, education attainment, regular exercise, drinking, smoking and additionally for the other components of the MetS (except for analyses on the MetS).

## Associations between high-normal 24-h UAE and MetS

Table 4 revealed that the odd of MetS was gradually elevated according to normal range 24-h UAE quartile. Multivariate-adjusted OR<sub>s</sub> of MetS were 1.22, 1.14 and 2.02 for 24-h UAE quartile 2, 3 and 4, compared with the lowest quartile ( $p < 0.001$ ). Furthermore, compared to the lowest 24-h UAE quartile, multivariate-adjusted OR of the highest quartile were 1.52 for hyperglycemia ( $p_{\text{trend}} < 0.01$ ). However, no significant association between normal range 24-h UAE and the other components of MetS were found.

Table 4. Normal range 24-h UAE quartiles associated with MetS and its components

	Odds Ratio (95% CI)				<i>p</i> -Value
	Q1	Q2	Q3	Q4	
Metabolic syndrome					
Model 1 <sup>a</sup>	1.00	1.24 (0.91, 1.67)	1.15 (0.84, 1.56)	2.03 (1.51, 2.72)	<.0001

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

		Odds Ratio (95% CI)				p-Value
		Q1	Q2	Q3	Q4	
Model 2 <sup>b</sup>		1.00	1.22 (0.90,1.65)	1.14 (0.84, 1.55)	2.02 (1.51,2.72)	<.0001
Central obesity						
Model 1 <sup>a</sup>		1.00	1.35 (0.94, 1.94)	1.07 (0.75, 1.55)	1.72 (1.19, 2.48)	0.0154
Model 2 <sup>b</sup>		1.00	1.29 (0.89, 1.88)	1.07 (0.73, 1.58)	1.53 (1.04, 2.25)	0.1221
High BP						
Model 1 <sup>a</sup>		1.00	1.18 (0.90, 1.54)	0.99 (0.75, 1.29)	1.43 (1.09, 1.87)	0.0253
Model 2 <sup>b</sup>		1.00	1.12 (0.85, 1.48)	0.93 (0.71, 1.23)	1.24 (0.94, 1.64)	0.1957
High triglycerides						
Model 1 <sup>a</sup>		1.00	0.96 (0.72, 1.26)	1.00 (0.76, 1.32)	1.43 (1.09, 1.87)	0.0092
Model 2 <sup>b</sup>		1.00	0.84 (0.63, 1.13)	0.93(0.69, 1.24)	1.18 (0.89, 1.56)	0.1242
Low HDL-C						
Model 1 <sup>a</sup>		1.00	1.37 (0.96, 1.93)	1.28 (0.90, 1.81)	1.55 (1.09, 2.20)	0.0953
Model 2 <sup>b</sup>		1.00	1.34 (0.93, 1.94)	1.26 (0.87, 1.83)	1.29 (0.89, 1.87)	0.4045
Hyperglycemia						
Model 1 <sup>a</sup>		1.00	1.12 (0.87, 1.44)	1.37 (1.07, 1.77)	1.72 (1.33, 2.21)	0.0001
Model 2 <sup>b</sup>		1.00	1.09 (0.84, 1.41)	1.34 (1.03, 1.74)	1.52 (1.17, 1.98)	0.0055

<sup>a</sup>Model 1: adjusted for age, sex;  
<sup>b</sup>Model 2: adjusted for age, sex, education attainment, regular exercise, drinking, smoking and additionally for the other components of the MetS (except for analyses on the MetS).

**DISCUSSION**

Our study showed the prevalence of MAU was 9.0% in the study population and much more prevalent in persons with MetS (15.1%) in particular. The prevalence of MAU in our study was moderate compared with that of other studies in China (4.1–15%) [13-14, 21-24]. This varied prevalence observed in the Chinese population may be associated with different age distribution, region, and method of defining MAU.

1  
2  
3 200 In the current study, the prevalence of MAU was consistently higher in persons with MetS than  
4  
5 201 those without MetS. The prevalence of MAU increased significantly with increasing proportions of MetS  
6  
7  
8 202 components after the subjects were divided by the number of MetS components. The same results were  
9  
10 203 obtained in previous studies [12-15, 25–26]. This finding indicates that a large number of participants  
11  
12 204 with MAU are easily overlooked in routine health examinations that do not include MAU measurements.  
13  
14  
15 205 This finding also suggests that intervention for MetS should be started at the earliest stage of renal injury.  
16

17 206 Furthermore, our study showed that MAU was significantly associated with MetS and its components  
18  
19 207 apart from central obesity and low HDL-C. Many epidemiologic studies suggested an independent  
20  
21  
22 208 association between MAU and MetS. However, findings on the associations between various  
23  
24 209 components of MetS components and MAU were controversial. Blood pressure and fasting glucose were  
25  
26 210 consistently found to be two main risk factors associated with MAU, which was also clearly shown in  
27  
28  
29 211 our study. However, the association between MAU and abdominal obesity, HDL and triglyceride were  
30  
31 212 inconsistent in previous studies [8, 9, 16]. Thus far, two studies have reported an association between  
32  
33 213 MAU and risk of MetS, with OR (95% CI) of 5.13 (1.96–13.45) and 2.71 (1.69–4.36) [14, 15], consistent  
34  
35 214 with our finding.  
36

37  
38 215 Our study further showed that MetS gradually increased with increasing normal range 24-h UAE  
39  
40 216 quartiles, which is consistent with previous studies [15, 26-28]. Thus far, only one prospective cohort  
41  
42 217 study reported hazard ratios with 95% CIs for MetS: 1.57 (1.14–2.18) for the three highest albumin-to-  
43  
44  
45 218 creatinine ratio quartiles compared to the lowest one [28]. However, the association between the  
46  
47 219 components of MetS and high-normal 24-h UAE were not exactly the same. Ge et al. reported that the  
48  
49 220 relationship between 24-h UAE within normal range and central obesity, elevated blood pressure and  
50  
51 221 elevated triglycerides was significant [15]. Another study also found that the association between low-  
52  
53  
54 222 grade albuminuria and the components of MetS was significant except for low HDL-C [25]. In our study,  
55  
56  
57  
58  
59  
60

1  
2  
3 223 the relationship between high-normal 24-h UAE and hyperglycemia in the general Chinese population  
4  
5  
6 224 was found. This association persisted after the adjustment for multiple risk factors.

7  
8 225 In our study, we found not only MAU but also elevated 24-h UAE within normal range had a  
9  
10 226 significant relationship with increased risk of MetS in Chinese adults. The magnitude of this association  
11  
12 227 persisted after controlling for traditional risk factors. Our finding has important public health implications  
13  
14  
15 228 for preventing MetS [15].

16  
17 229 Our study had strengths. First, we used 24-h UAE to define microalbuminuria in a relatively large  
18  
19 230 sample population, which was more accurate than most previous studies in the general Chinese  
20  
21  
22 231 population. Furthermore, our study rigorously conducted standardized methods and quality control for  
23  
24 232 data collection. However, our study had several limitations. First, due to investigative convenience, we  
25  
26 233 did not use an objective biomarker such as para-aminobenzoic acid to assess complete 24-h urine [29].  
27  
28 234 We assessed the completeness by measuring urinary volume and creatinine concentration in the present  
29  
30  
31 235 study. Second, we did not evaluate the renal function of the subjects, which may cause some bias in the  
32  
33 236 results. Finally, because this study had a cross-sectional design, it was difficult to interpret a causal  
34  
35 237 association between MAU and 24-h UAE with MetS and its components. Therefore, future prospective  
36  
37  
38 238 studies are recommended to confirm our findings.

39  
40 239 **CONCLUSIONS**

41  
42  
43 240 Our study confirmed both MAU and high-normal 24-h UAE were stronger risk factors for MetS in the  
44  
45 241 general Chinese population. Assessment of these risk factors can open a window of opportunity for  
46  
47 242 early intervention to decrease the effects of MetS in China.

48  
49  
50 243  
51  
52 244 **Acknowledgements** Special thanks to Prof. Jixiang Ma for his great contribution to the project  
53  
54  
55 245 initiation. We would such as to express our sincere appreciation to all staff for performing the field work.

We are also grateful to all the study participants.

**Contributions** JM, XC, JW designed the study and supervised data collection. JX, LY, XC, XG, and YZ participated in field work and data collection. JX and LY analyzed the data. JX wrote the manuscript to which all the authors contributed. JM and JW critically revised the manuscript for important intellectual content. All the authors reviewed and approved the final manuscript.

**Funding** The survey was supported by Shandong-Ministry of Health Action on Salt Reduction and Hypertension (No.2013) and the Young Scholar Scientific Research Foundation of the Chinese Center for Disease Control and Prevention (No. 2018A203).

**Competing interests** None declared.

**Ethics approval** The survey was approved by the Ethics Committee of the National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** No additional data are available.

## References

1. Chronic Kidney Disease Prognosis C, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet* 2010;375:2073-81.
2. Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. *Kidney Int* 2011;80:93-104.
3. Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. *Kidney Int* 2011;79:1331-40.



1  
2  
3 271 4. Van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher  
4 albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis  
5 272 of high-risk population cohorts. *Kidney Int* 2011;79:1341–52.  
6 273  
7 274 5. Chen YY, Li YY, Lu YH, Albuminuria independently predicts cardiovascular and all-cause mortality  
8 in a middle-aged and elderly Chinese population. *Scand J Clin Lab Invest* 2012;72:281-6.  
9 275  
10 276 6. Yuyun MF, Khaw KT, Luben R, et al. Microalbuminuria independently predicts all-cause and  
11 cardiovascular mortality in a British population: The European Prospective Investigation into Cancer  
12 277 in Norfolk (EPIC-Norfolk) population study. *Int J Epidemiol* 2004;33:189-98.  
13 278  
14 279 7. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A Consensus  
15 Statement from the International Diabetes Federation. *Diabet Med* 2006;23:469-80.  
16 280  
17 281 8. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the  
18 metabolic syndrome: NHANES III. *Am J Hypertens* 2003;16:952-8.  
19 282  
20 283 9. Hao Z, Konta T, Takasaki S, et al. The association between microalbuminuria and metabolic  
21 syndrome in the general population in Japan: the Takahata study. *Intern Med* 2007;46:341-6.  
22 284  
23 285 10. Choi HS, Ryu SH, Lee KB. The relationship of microalbuminuria with metabolic syndrome.  
24 *Nephron Clin Pract* 2006;104:85-93.  
25 286  
26 287 11. Klausen KP, Parving HH, Scharling H, et al. The association between metabolic syndrome,  
27 microalbuminuria and impaired renal function in the general population: impact on cardiovascular  
28 288 disease and mortality. *J Intern Med* 2007;262:470-8.  
29 289  
30 290 12. Lee HO, Bak HJ, Shin JY, et al. Association between Metabolic Syndrome and Microalbuminuria in  
31 Korean Adults. *Korean J Fam Med* 2015;36:60-71.  
32 291  
33 292 13. Chen B, Yang D, Chen Y, et al. The prevalence of microalbuminuria and its relationships with the  
34 components of metabolic syndrome in the general population of China. *Clin Chim Acta*  
35 293 2010;411:705-9.  
36 294  
37 295 14. Sheng CS, Hu BC, Fan WX, et al. Microalbuminuria in relation to the metabolic syndrome and its  
38 components in a Chinese population. *Diabetol Metab Syndr* 2011;3:6.  
39 296  
40 297 15. Ge Z, Guo X, Chen X, et al. Are Microalbuminuria and Elevated 24 H Urinary Microalbumin  
41 Excretion within Normal Range Associated with Metabolic Syndrome in Chinese Adults? *PLoS One*  
42 298 2015;10:e0138410.  
43 299  
44 300 16. Lee YY, Yang CK, Weng YM, et al. All Components of Metabolic Syndrome Are Associated with  
45 Microalbuminuria in a Chinese Population. *PLoS One* 2016;11:e0157303.  
46 301  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

17. Thoenes M, Bramlage P, Khan BV, et al. Albuminuria: pathophysiology, epidemiology and clinical relevance of an emerging marker for cardiovascular disease. *Future Cardiol* 2007;3:519-24.
18. Crews DC, Boulware LE, Gansevoort RT, et al. Albuminuria: is it time to screen the general population? *Adv Chronic Kidney Dis* 2011;18:249-57.
19. Xu J, Chen X, Ge Z, et al. Associations of Usual 24-Hour Sodium and Potassium Intakes with Blood Pressure and Risk of Hypertension among Adults in China's Shandong and Jiangsu Provinces. *Kidney Blood Press Res* 2017;42:188-200.
20. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 2009;120:1640-5.
21. Shan Y, Zhang Q, Liu Z, et al. Prevalence and risk factors associated with chronic kidney disease in adults over 40 years: a population study from Central China. *Nephrology (Carlton)* 2010;15:354-61.
22. Hao G, Wang Z, Zhang L, et al. Prevalence of microalbuminuria among middle-aged population of china: a multiple center cardiovascular epidemiological study. *Angiology* 2015; 66:49-56.
23. Chen W, Chen W, Wang H, et al. Prevalence and risk factors associated with chronic kidney disease in an adult population from southern China. *Nephrol Dial Transplant* 2009;24:1205-12.
24. Yan L, Ma J, Guo X, et al. Urinary albumin excretion and prevalence of microalbuminuria in a general Chinese population: a cross-sectional study. *BMC Nephrol* 2014;15:165.
25. Zhang J, Chen Y, Xu Y, et al. Low-Grade Albuminuria Is Associated with Metabolic Syndrome and Its Components in Middle-Aged and Elderly Chinese Population. *PloS one* 2013; 8: e65597.
26. Li MF, Feng QM, Li LX, et al. High-normal urinary albumin-to-creatinine ratio is independently associated with metabolic syndrome in Chinese patients with type 2 diabetes mellitus: A cross-sectional community-based study. *J Diabetes Investig* 2015; 6:354-9.
27. Park SY, Park YK, Cho KH, et al. Normal range albuminuria and metabolic syndrome in South Korea: the 2011-2012 Korean National Health and Nutrition Examination Survey. *PloS one* 2015;10:e0125615.
28. Oh CM, Park SK, Kim HS, et al. High-normal albuminuria predicts metabolic syndrome in middle-aged Korean men: a prospective cohort study. *Maturitas* 2014;77:149-54.
29. Murakami K, Sasaki S, Takahashi Y, et al. Sensitivity and specificity of published strategies using

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

urinary creatinine to identify incomplete 24-h urine collection. *Nutrition* 2008; 24:16-22.

**Figure 1.** Prevalence of MAU (panel A) and mean 24-h UAE (panel B) according to the number of MetS components.

For peer review only




Figure 1. Prevalence of MAU (panel A) and mean 24-h UAE (panel B) according to the number of MetS components.

# BMJ Open

## Association of microalbuminuria and high-normal 24-hour urinary albumin excretion with metabolic syndrome and its components in the general Chinese population: a cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031443.R1
Article Type:	Original research
Date Submitted by the Author:	17-Aug-2019
Complete List of Authors:	Xu, Jianwei; National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Ma, Jixiang; Chinese Center for Disease Control and Prevention Chen, Xiaorong; National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention Yan, Liuxia; National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention Cai, Xiaoning; National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention Guo, Xiaolei; Shandong Center for Disease Control and Prevention Zhang, Yongqing; Jiangsu Center for Disease Control and Prevention Wu, Jing; National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Epidemiology, Public health
Keywords:	Metabolic Syndrome, Microalbuminuria, Urinary Albumin

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Association of microalbuminuria and high-normal 24-hour urinary albumin excretion with metabolic syndrome and its components in the general Chinese population: a cross-sectional study**

**Jianwei Xu<sup>1</sup>, Jixiang Ma<sup>2</sup>, Xiaorong Chen<sup>1</sup>, Liuxia Yan<sup>1</sup>, Xiaoning Cai<sup>1</sup>, Xiaolei Guo<sup>3</sup>, Yongqing Zhang<sup>4</sup>, Jing Wu<sup>1\*</sup>**

1 National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China, 2 Chinese Center for Disease Control and Prevention, Beijing, China, 3 Shandong Center for Disease Control and Prevention, Jinan, China, 4 Jiangsu Center for Disease Control and Prevention, Nanjing, China

Jianwei Xu, xujianwei@ncncd.chinacdc.cn;

Jixiang Ma, majix@163.com;

Xiaorong Chen, chenxiaorong@ncncd.chinacdc.cn;

Liuxia Yan, yanliuxia@ncncd.chinacdc.cn;

Xiaoning Cai, caixiaoning@ncncd.chinacdc.cn;

Xiaolei Guo, guoxiaolei@126.com;

Yongqing Zhang, zyzq6943@163.com;

\*Corresponding author: Jing Wu, E-mail: wujing@ncncd.chinacdc.cn.

## Abstract

**Objective:** Microalbuminuria has been described as a risk factor for metabolic syndrome (MetS). However, the association between MetS components with microalbuminuria and 24-h urinary albumin excretion (UAE) has not been clearly explained in the general Chinese population. We aimed to analyze the association between microalbuminuria and high-normal 24-h UAE with MetS and its components.

**Design:** Cross-sectional observational study.

**Setting:** Four selected counties/districts in China's Shandong and Jiangsu Provinces.

**Participants:** A total of 2261 participants aged 18-69 years were included in this study. Participants with missing data on physical examination or incomplete urine collection are not included in the analysis.

**Results:** The prevalence of microalbuminuria was 9.0%, and the mean 24-h UAE was 18.0 mg/d. The prevalence of microalbuminuria was significantly higher for the MetS, high blood pressure, high triglycerides, low high-density lipoprotein cholesterol (HDL-C) and hyperglycemia groups, but not for central obesity. Both microalbuminuria and mean 24-h UAE were significantly increased with a number of MetS components. The adjusted odds ratio (OR) and 95% confidence interval (CI) for MetS with microalbuminuria was 2.95 (2.15 to 4.04) compared to those without microalbuminuria. Microalbuminuria patients were significantly associated with three components of MetS: high blood pressure, high triglycerides and hyperglycemia with OR=1.86, 95% CI 1.31 to 2.64; OR=1.80, 95% CI 1.31 to 2.46; and OR=1.84, 95% CI 1.34 to 2.53, respectively. No significant association of microalbuminuria and central obesity, low HDL-C was found. The presence of MetS were gradually elevated according to the normal range 24-h UAE quartiles: OR=1.00, OR=1.22, OR=1.14 and OR=2.02, respectively. Hyperglycemia was also significantly increased according to the normal range

24-h UAE quartiles.

**Conclusions:** Microalbuminuria and elevated 24-h UAE within normal range were closely associated with MetS in the Chinese population, which may provide a basis for the development of early intervention to decrease the effects of MetS.

**Keywords:** Metabolic Syndrome; Microalbuminuria; Urinary Albumin

## Strengths and limitations of this study

- We used 24-h UAE to define microalbuminuria, which was more accurate than most previous studies.
- This is the largest sample size of the general Chinese population collected 24-h urine.
- We explore the association between high-normal 24-h UAE with MetS and its components.
- This causal relationship between microalbuminuria and MetS cannot be demonstrated in our cross-sectional study.

## INTRODUCTION

Microalbuminuria (MAU), defined by abnormally high albumin excretion (30-300 mg/d) in a 24-h urine sample, was significantly associated with chronic kidney disease, cardiovascular disease and progression of end-stage renal disease independent of traditional risk factors.[1–4] Prospective and epidemiologic studies have found that MAU is also a powerful predictor of all-cause and cardiovascular mortality in the general population. [5-6]

Metabolic syndrome (MetS) is a widely accepted description of a cluster of metabolic abnormalities characterized by obesity, hypertension, dyslipidemia and hyperglycemia. [7] Some



studies have evaluated the relationship between MetS and MAU as a marker for early-stage chronic kidney disease.[8-11] Significant associations between MetS and MAU have been demonstrated in the Japanese, [9] Korean, [10, 12]and Chinese populations. [13-16] However, data concerning the relationship between individual MetS components and MAU were inconsistent, and a causal relationship between MAU and MetS remains unclear despite the predictive value MAU has shown in the aforementioned studies. Furthermore, the study of the association between normal range 24-h urinary albumin excretion (UAE) and MetS components has been limited. [15]

The amount of 24-h UAE is considered the ‘gold standard’ for defining MAU. [17, 18] However, most of the previous studies of MAU in the Chinese population commonly used an early morning or random spot urine sample instead of measuring 24-h UAE. Therefore, in this study, we investigated the prevalence of MAU by analyzing 24-h UAE and analyzed the association between MAU and normal range 24-h UAE with MetS and its components.

## METHODS

### Study participants

Data were derived from the supplemental baseline survey of the Shandong Ministry of Health Action on Salt Reduction and Hypertension project, which was a cross-sectional survey conducted at four sites in the Shandong and Jiangsu provinces during 2013 and 2014. We used a stratified, multistage sampling method to select the participants. We selected 80 villages or communities in four sites using proportional probability sampling. Random sample of 120 adults aged 18-69 years were drawn from each villages or communities. A total of 9600 participants were invited to participate in the survey and physical examination. Random sample of at least 30 adults were drawn among 120 adults from each villages or communities. Finally, a subsample of 2408 participants collected a single 24-h urine sample.

1  
2  
3 92 Participants with the following conditions were not required to provide urine samples: (1) patients who  
4  
5 93 had difficulty collecting a urine sample; (2) patients with acute and chronic urinary infection; (3)  
6  
7  
8 94 women who were pregnant, breastfeeding, or actively menstruating; and (4) patients with severe  
9  
10 95 vomiting and diarrhea. We excluded 3 subjects with missing data from their physical examination or  
11  
12 96 blood samples and 127 participants with incomplete 24-h urine collection. For the purpose of the  
13  
14  
15 97 present study on microalbuminuria, we also excluded 17 subjects with macroalbuminuria, or a 24-h  
16  
17 98 UAE >300 mg/d. Therefore, a total of 2261 participants were included in this study.  
18

19 99 Our study was approved by the ethics committee of the National Center for Chronic and  
20  
21  
22 100 Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention  
23  
24 101 (201311). Written informed consent was obtained from all participants.  
25

26 102 **Demographic, anthropometrical and biochemical data collection**  
27  
28

29 103 A face-to-face interview was conducted by local trained health professionals using a standard  
30  
31  
32 104 questionnaire. Relevant variables included age, sex, educational level, smoking status, alcohol intake,  
33  
34 105 regular exercise and previous diagnosis and treatment of hypertension and diabetes. During physical  
35  
36 106 examination, height, weight, waist circumference (WC) and blood pressure (BP) were measured by  
37  
38  
39 107 trained researchers using standardized protocols and techniques. Weight and height were measured  
40  
41 108 with participants dressed in light, indoor clothing without shoes by standardized techniques and  
42  
43 109 calibrated equipment. The waist circumference was measured at the narrowest point between the lower  
44  
45  
46 110 border of the rib cage and the iliac crest. The body mass index (BMI) was calculated as the weight in  
47  
48 111 kilograms divided by the height in meters squared (kg/m<sup>2</sup>). Blood pressure was measured three times  
49  
50 112 by electronic sphygmomanometer (HEM-7071, Omron Corporation, Japan), and the final blood  
51  
52 113 pressure was obtained by averaging the three measurements.  
53

54  
55 114 Fasting blood samples collected from each participant were processed and shipped in cold storage  
56  
57  
58  
59  
60

to a certified laboratory (ADICON Clinical Laboratory Inc., Jinan, China). Fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were measured. Plasma glucose was measured using a modified hexokinase enzymatic method. Serum cholesterol and triglyceride levels were analyzed enzymatically using commercially available reagents.

## 24-h Urine collection and analysis

Eligible participants were instructed not to change their dietary and lifestyle habits. We provided a standard plastic container for each participant to collect a 24-h urine sample. Trained researchers gave each participant both written and verbal instructions on how to collect a 24-h urine sample. Health professionals carefully explained to the subjects the purpose of the 24-h urine collection and asked the subjects to correctly repeat the information. The exact 24-h urine collection time, including starting and ending times, was recorded by the supervising health professional. The total volume of the collection was measured by a laboratory technician, and urine aliquots were frozen at  $-20^{\circ}\text{C}$  about 30 days and shipped to ADICON Clinical Laboratory in Jinan. Urinary creatinine was measured by the picric acid method. UAE was measured with an immunonephelometric method using the Olympus AU640 Analyzer, for which the coefficient of variation was 3.0%. Either a 24-h urinary volume less than 500 ml or a 24-h urinary creatinine volume that was  $\pm 2$  standard deviations (SD) outside of the sex-specific mean, 0.98 to 16.17 mmol/l for men and 0.93 to 13.60 mmol/l for women, was defined as an incomplete urine collection. [19]

## Definition of the metabolic syndrome

We adopted the harmonized criteria of MetS, which defines MetS as the presence of  $\geq 3$  of the following risk factors [20]: central obesity defined as a WC  $\geq 90$  cm in men and  $\geq 80$  cm in women; high BP defined as a systolic blood pressure (SBP)  $\geq 130$  mmHg, a diastolic blood pressure (DBP)  $\geq 85$

1  
2  
3 138 mmHg or undergoing treatment with an antihypertensive medication; high triglycerides defined as a  
4  
5  
6 139 fasting plasma TC level  $\geq 1.7$  mmol/l or drug treatment for increased TC; low HDL-C defined as  
7  
8 140 HDL-C  $< 1.0$  mmol/l in men and  $< 1.3$  mmol/l in women or drug treatment for increased HDL-C; or  
9  
10 141 hyperglycemia defined as FBG level  $\geq 5.6$  mmol/l or undergoing drug treatment for increased FBG.  
11  
12

13 142 **Statistical analysis**  
14  
15

16 143 Continuous variables were presented as the mean (SD), and categorical variables were presented as  
17  
18 144 percentages. According to their quartiles of 24-h UAE with normal range (n=2058), study subjects  
19  
20 145 were divided into four groups: Q1, 0–9.38mg/d; Q2, 9.39–11.96 mg/d; Q3, 11.97–15.46 mg/d; and Q4,  
21  
22 146 15.47–29.99 mg/d.  
23  
24

25 147 We performed logistic regression analyses to study the association of MAU and 24-h UAE with  
26  
27 148 MetS and its components, while controlling for covariates including sociodemographic factors (age,  
28  
29 149 sex, education level) and lifestyle factors (regular exercise, alcohol intake and smoking). Participants  
30  
31 150 who were without microalbuminuria or were in the Q1 group were used as a reference group to  
32  
33 151 estimate the odds ratios (ORs) and 95% confidence intervals (CIs). Tests of linear trends across  
34  
35 152 increasing quartiles of 24-h UAE were conducted by treating the medians of the average 24-h UAE as a  
36  
37 153 continuous variable in the logistic regression models. Statistical analyses were performed with SAS 9.3  
38  
39 154 (SAS Institute Inc.). Tests performed were two-sided, and a *p*-value  $< 0.05$  was considered statistically  
40  
41 155 significant.  
42  
43  
44  
45

46 156 **Patient and public involvement**  
47  
48

49 157 Patients and the public were not involved in the design or planning of the study.  
50  
51  
52 158  
53  
54

55 159 **RESULTS**  
56  
57  
58  
59  
60

## Characteristics of subjects

Among the 2261 participants, the prevalence of MAU was 9.0% (203), and prevalence was not statistically significantly different between males and females (8.8% vs. 9.1%,  $p=0.08$ ). The mean 24-h UAE was 18.0 mg/d. The population's characteristics were summarized according to microalbuminuria and normal range 24-h UAE quartiles in Table 1. Compared to those without MAU, participants with MAU were more likely to have higher WC, BMI, SBP and DBP, FBG and TG. Similarly, these variables were also statistically significant among increasing quartiles of 24-h UAE.

Table 1. General characteristics of the study participants

	Normal range 24-h UAE (mg/d)				<i>p</i> -value	Microalbuminuria		<i>p</i> -value
	Q1	Q2	Q3	Q4		No	Yes	
Number of subjects	515	515	516	512		2058	203	
Age (years)	41.7(13.5)	42.5(13.5)	41.8(13.5)	42.5(13.3)	0.67	42.1(13.5)	41.4(13.5)	0.48
Men (%)	51.8	48.2	50.8	48.4	0.57	49.8	48.8	0.78
BMI (kg/cm <sup>2</sup> )	24.4(3.6)	24.6(3.6)	24.7(3.9)	25.5(3.9)	<0.001	24.8(3.8)	26.0(4.5)	<0.001
WC (cm)	82.3(9.1)	82.4(9.6)	82.7(9.9)	84.8(10.5)	<0.001	83.0(9.8)	85.8(12.5)	<0.001
SBP (mmHg)	129.5(19.4)	130.7(18.5)	129.8(18.7)	133.1(20.7)	0.0111	130.8(19.4)	136.1(23.3)	<0.001
DBP (mmHg)	81.8(11.4)	83.1(10.8)	82.5(11.4)	84.9(12.2)	<0.001	83.1(11.5)	87.9(14.4)	<0.001
High-school (%)	24.1	21.9	23.1	25.4	0.61	23.6	26.6	0.34
Smoking (%)	30.1	29.1	29.1	27.3	0.80	28.9	33.0	0.22
Drinker (%)	23.7	27.6	26.2	27.3	0.47	26.2	27.1	0.78
Regular exercise (%)	17.3	16.7	22.3	22.3	0.03	19.6	30.5	<0.001
FBG (mmol/L)	5.6(1.1)	5.6(1.0)	5.7(1.1)	6.0(1.7)	<0.001	5.7(1.3)	6.5(2.4)	<0.001
TC (mmol/L)	4.7(0.9)	4.8(0.9)	4.8(0.9)	4.9(1.0)	0.0281	4.8(0.9)	5.1(1.0)	<0.001
HDL (mmol/L)	1.3(0.3)	1.3(0.3)	1.3(0.3)	1.2(0.3)	0.0203	1.3(0.3)	1.2(0.3)	0.03
LDL (mmol/L)	2.4(0.7)	2.4(0.6)	2.5(0.7)	2.5(0.7)	0.0186	2.4(0.7)	2.5(0.7)	0.06
TG (mmol/L)	1.4(1.2)	1.4(1.3)	1.5(1.4)	1.8(2.1)	<0.001	1.6(1.6)	2.3(2.4)	<0.001
Creatinine (mmol/d)	6.0(2.2)	7.4(2.6)	8.0(3.2)	8.6(3.1)	<0.001	7.5(3.0)	8.8(3.1)	<0.001
24-h UAE (mg/d)	7.7(1.2)	10.7(0.8)	13.5(1.0)	20.1(3.7)	<0.001	13.0(5.0)	68.8(50.4)	<0.001

## MAU and 24-h UAE by the number of MetS components

The prevalence of MAU in MetS and its components are shown in Table 2. The prevalence of MAU

1  
2  
3 171 was significantly higher for the MetS, high BP, high triglycerides and hyperglycemia groups. The  
4  
5 172 prevalence of MAU for subjects with 0 (n=342), 1 (n=632), 2 (n=632), 3 (n=433), and 4 or 5 (n=222)  
6  
7  
8 173 components of MetS were 5.0, 5.5, 8.2, 14.5 and 16.2%, respectively. The corresponding mean 24-h  
9  
10 174 UAE measurements were 14.5, 15.1, 17.9, 22.7 and 22.8 mg/d. In aggregate, both the prevalence of  
11  
12 175 MAU and the mean 24-h UAE were significantly elevated according to the number of MetS  
13  
14  
15 176 components with all *p*-values <0.001 (Fig 1).

16  
17 177 Table 2. Association of microalbuminuria and MetS and its components  
18

Components	Microalbuminuria (%)		<i>p</i> -value
	No (n=2058)	Yes (n=203)	
Central obesity			
No	91.49	8.51	0.1982
Yes	89.76	10.24	
High BP			
No	93.52	6.48	<0.001
Yes	88.85	11.15	
High triglycerides			
No	93.11	6.89	<0.001
Yes	86.18	13.82	
Low HDL-C			
No	91.81	8.19	0.0249
Yes	88.72	11.28	
Hyperglycemia			
No	93.94	6.06	<0.0001
Yes	87.78	12.22	
Metabolic syndrome			
No	93.52	6.48	<0.0001
Yes	84.89	15.11	

55 178

56  
57  
58  
59  
60

## Association between MAU and MetS components

The association between MAU and the components of MetS are shown in Table 3. Compared with participants without microalbuminuria, the age- and gender-adjusted OR (95% CI) for MetS with microalbuminuria was 2.93 (2.15 to 4.00), and the multivariate-adjusted OR (95% CI) was 2.95 (2.15 to 4.04). For MetS components, both age- and gender-adjusted and multivariate-adjusted, MAU was strongly associated with high BP, high triglycerides and hyperglycemia. However, no significant association between MAU and central, obesity low HDL-C was found.

Table 3. Relationship between MAU and metabolic syndrome components

	No. of cases	without Microalbuminuria	Microalbuminuria	
			Model 1 <sup>a</sup>	Model 2 <sup>b</sup>
Metabolic syndrome	655	1.00	2.93 (2.15 to 4.00)	2.95 (2.15 to 4.04)
Central obesity	615	1.00	1.40 (0.92 to 2.13)	1.02 (0.65 to 1.60)
High BP	1211	1.00	2.20 (1.57 to 3.09)	1.86 (1.31 to 2.64)
High triglycerides	680	1.00	2.21 (1.65 to 2.97)	1.80 (1.31 to 2.46)
Low HDL-C	576	1.00	1.71 (1.13 to 2.60)	1.32 (0.85 to 2.04)
Hyperglycemia	1072	1.00	2.28 (1.68 to 3.11)	1.84 (1.34 to 2.53)

<sup>a</sup>Model 1: adjusted for age, sex;

<sup>b</sup>Model 2: adjusted for age, sex, education attainment, regular exercise, drinking, smoking and additionally for the other components of the MetS (except for analyses on the MetS).

## Associations between high-normal 24-h UAE and MetS

Table 4 revealed that the odd of MetS was gradually elevated according to normal range 24-h UAE quartile. Multivariate-adjusted OR<sub>S</sub> of MetS were 1.22, 1.14 and 2.02 for 24-h UAE quartile 2, 3 and 4,

1  
2  
3 194 compared with the lowest quartile ( $p<0.0001$ ). Furthermore, compared to the lowest 24-h UAE quartile,  
4  
5 195 multivariate-adjusted OR of the highest quartile were 1.52 for hyperglycemia ( $p<0.01$ ). However, no  
6  
7  
8 196 significant association between normal range 24-h UAE and the other components of MetS were found.  
9  
10

11 197 Table 4. Normal range 24-h UAE quartiles associated with MetS and its components

		Odds Ratio (95% CI)				<i>p</i> -Value
		Q1	Q2	Q3	Q4	
Metabolic syndrome						
	Model 1 <sup>a</sup>	1.00	1.24 (0.91 to 1.67)	1.15 (0.84 to 1.56)	2.03 (1.51 to 2.72)	<0.0001
	Model 2 <sup>b</sup>	1.00	1.22 (0.90 to 1.65)	1.14 (0.84 to 1.55)	2.02 (1.51 to 2.72)	<0.0001
Central obesity						
	Model 1 <sup>a</sup>	1.00	1.35 (0.94 to 1.94)	1.07 (0.75 to 1.55)	1.72 (1.19 to 2.48)	0.0154
	Model 2 <sup>b</sup>	1.00	1.29 (0.89 to 1.88)	1.07 (0.73 to 1.58)	1.53 (1.04 to 2.25)	0.1221
High BP						
	Model 1 <sup>a</sup>	1.00	1.18 (0.90 to 1.54)	0.99 (0.75 to 1.29)	1.43 (1.09 to 1.87)	0.0253
	Model 2 <sup>b</sup>	1.00	1.12 (0.85 to 1.48)	0.93 (0.71 to 1.23)	1.24 (0.94 to 1.64)	0.1957
High triglycerides						
	Model 1 <sup>a</sup>	1.00	0.96 (0.72 to 1.26)	1.00 (0.76 to 1.32)	1.43 (1.09 to 1.87)	0.0092
	Model 2 <sup>b</sup>	1.00	0.84 (0.63 to 1.13)	0.93(0.69 to 1.24)	1.18 (0.89 to 1.56)	0.1242
Low HDL-C						
	Model 1 <sup>a</sup>	1.00	1.37 (0.96 to 1.93)	1.28 (0.90 to 1.81)	1.55 (1.09 to 2.20)	0.0953
	Model 2 <sup>b</sup>	1.00	1.34 (0.93 to 1.94)	1.26 (0.87 to 1.83)	1.29 (0.89 to 1.87)	0.4045
Hyperglycemia						
	Model 1 <sup>a</sup>	1.00	1.12 (0.87 to 1.44)	1.37 (1.07 to 1.77)	1.72 (1.33 to 2.21)	0.0001
	Model 2 <sup>b</sup>	1.00	1.09 (0.84 to 1.41)	1.34 (1.03 to 1.74)	1.52 (1.17 to 1.98)	0.0055

48 198 <sup>a</sup>Model 1: adjusted for age, sex;

49  
50 199 <sup>b</sup>Model 2: adjusted for age, sex, education attainment, regular exercise, drinking, smoking and  
51  
52 200 additionally for the other components of the MetS (except for analyses on the MetS).

53 201  
54 202

55  
56 203 **DISCUSSION**

57  
58  
59  
60



Our study showed the prevalence of MAU was 9.0% in the study population and much more prevalent in persons with MetS (15.1%) in particular. The prevalence of MAU in our study was moderate compared with that of other studies in China (4.1% to 15%).<sup>[13-14, 21-24]</sup> This varied prevalence observed in the Chinese population may be associated with different age distribution, region, and method of defining MAU.

In the current study, the prevalence of MAU was consistently higher in persons with MetS than those without MetS. The prevalence of MAU increased significantly with increasing proportions of MetS components after the subjects were divided by the number of MetS components. The same results were obtained in previous studies. <sup>[12-15, 25-26]</sup> This finding indicates that a large number of participants with MAU are easily overlooked in routine health examinations that do not include MAU measurements. This finding also suggests that intervention for MetS should be started at the earliest stage of renal injury.

Furthermore, our study showed that MAU was significantly associated with MetS and its components apart from central obesity and low HDL-C. Many epidemiologic studies suggested an independent association between MAU and MetS. However, findings on the associations between various components of MetS components and MAU were controversial. Blood pressure and fasting glucose were consistently found to be two main risk factors associated with MAU, which was also clearly shown in our study. However, the association between MAU and abdominal obesity, HDL and triglyceride were inconsistent in previous studies. <sup>[8, 9, 16]</sup> Thus far, two studies have reported an association between MAU and risk of MetS, with OR (95% CI) of 5.13 (1.96 to 13.45) and 2.71 (1.69 to 4.36), <sup>[14, 15]</sup> consistent with our finding.

Our study further showed that MetS gradually increased with increasing normal range 24-h UAE quartiles, which is consistent with previous studies. <sup>[15, 26-28]</sup> Thus far, only one prospective cohort

1  
2  
3 227 study reported hazard ratios with 95% CIs for MetS: 1.57 (1.14 to 2.18) for the three highest  
4  
5 228 albumin-to-creatinine ratio quartiles compared to the lowest one. [28] However, the association  
6  
7  
8 229 between the components of MetS and high-normal 24-h UAE were not exactly the same. Ge et al.  
9  
10 230 reported that the relationship between 24-h UAE within normal range and central obesity, elevated  
11  
12 231 blood pressure and elevated triglycerides was significant. [15] Another study also found that the  
13  
14  
15 232 association between low-grade albuminuria and the components of MetS was significant except for low  
16  
17 233 HDL-C. [25] In our study, the relationship between high-normal 24-h UAE and hyperglycemia in the  
18  
19 234 general Chinese population was found. This association persisted after the adjustment for multiple risk  
20  
21  
22 235 factors.

23  
24 236 In our study, we found not only MAU but also elevated 24-h UAE within normal range had a  
25  
26 237 significant relationship with increased risk of MetS in Chinese adults. The magnitude of this  
27  
28  
29 238 association persisted after controlling for traditional risk factors. Our finding has important public  
30  
31 239 health implications for preventing MetS. [15] The prevalence of MetS in China was 24.2%, [29] which  
32  
33 240 is becoming a serious public health problem in China. Our findings demonstrated that the lowering of  
34  
35 241 24 h UAE even within normal range should be an important priority for reducing the effects of MetS.  
36  
37  
38 242 Our study suggested clinicians should carefully evaluate the risk of MetS with normal rang UAE.  
39  
40 243 Annual MAU screening in MetS population should be an essential part of our preventive medicine  
41  
42 244 efforts. Policy makers should support such screening as part of the universal coverage policy programs.

44  
45 245 Our study had strengths. First, we used 24-h UAE to define microalbuminuria in a relatively large  
46  
47 246 sample population, which was more accurate than most previous studies in the general Chinese  
48  
49 247 population. Furthermore, it is a population-based epidemiologic study found the association between  
50  
51  
52 248 high-normal 24-h UAE and Mets, which is the difference from most previous studies in China. In  
53  
54 249 addition, our study rigorously conducted standardized methods and quality control for data

collection. However, our study had several limitations. First, due to investigative convenience, we did not use an objective biomarker such as para-aminobenzoic acid to assess complete 24-h urine. [30] We assessed the completeness by measuring urinary volume and creatinine concentration in the present study. Second, we did not evaluate the renal function of the subjects, which may cause some bias in the results. Third, although multiple covariates had been included in the adjustment, some potential confounding factors, such as dietary intake, [31] other medications could not be ruled out. Finally, because this study had a cross-sectional design, it was difficult to interpret a causal association between MAU and 24-h UAE with MetS and its components. Therefore, future prospective studies are recommended to confirm our findings.

## CONCLUSIONS

Our study confirmed both MAU and high-normal 24-h UAE were stronger risk factors for MetS in the general Chinese population. Assessment of these risk factors can open a window of opportunity for early intervention to decrease the effects of MetS in China.

**Acknowledgements** Special thanks to Prof. Jixiang Ma for his great contribution to the project initiation. We would such as to express our sincere appreciation to all staff for performing the field work. We are also grateful to all the study participants.

**Contributions** JM, XC, JW designed the study and supervised data collection. JX, LY, XC, XG, and YZ participated in field work and data collection. JX and LY analyzed the data. JX wrote the manuscript to which all the authors contributed. JM and JW critically revised the manuscript for important intellectual content. All the authors reviewed and approved the final manuscript.

**Funding** The survey was supported by Shandong-Ministry of Health Action on Salt Reduction and Hypertension (No.2013) and the Young Scholar Scientific Research Foundation of the Chinese Center

1  
2  
3 273 for Disease Control and Prevention (No. 2018A203).  
4  
5  
6 274 **Competing interests** None declared.  
7  
8 275 **Ethics approval** The survey was approved by the Ethics Committee of the National Center for  
9  
10 276 Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control  
11  
12 277 and Prevention.  
13  
14  
15 278 **Provenance and peer review** Not commissioned; externally peer reviewed.  
16  
17 279 **Data sharing statement** A de-identified minimal data set that underlies the findings and conclusions  
18  
19 280 described in the manuscript can be shared upon request by the editors to verify the reported study  
20  
21 281 findings.  
22  
23  
24 282

25  
26  
27 283 **References**

28  
29  
30 284 1. Chronic Kidney Disease Prognosis C, Matsushita K, van der Velde M, et al. Association of  
31  
32 285 estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in  
33 286 general population cohorts: a collaborative meta-analysis. *Lancet* 2010;375:2073-81.  
34  
35 287 2. Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher  
36  
37 288 albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general  
38 289 and high-risk population cohorts. *Kidney Int* 2011;80:93-104.  
39  
40 290 3. Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and  
41  
42 291 higher albuminuria are associated with mortality and end-stage renal disease. A collaborative  
43  
44 292 meta-analysis of kidney disease population cohorts. *Kidney Int* 2011;79:1331-40.  
45 293 4. Van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and  
46  
47 294 higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative  
48  
49 295 meta-analysis of high-risk population cohorts. *Kidney Int* 2011;79:1341-52.  
50  
51 296 5. Chen YY, Li YY, Lu YH, Albuminuria independently predicts cardiovascular and all-cause  
52 297 mortality in a middle-aged and elderly Chinese population. *Scand J Clin Lab Invest*  
53  
54 298 2012;72:281-6.  
55  
56 299 6. Yuyun MF, Khaw KT, Luben R, et al. Microalbuminuria independently predicts all-cause and  
57

- cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. *Int J Epidemiol* 2004;33:189-98.
7. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med* 2006;23:469-80.
  8. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. *Am J Hypertens* 2003;16:952-8.
  9. Hao Z, Konta T, Takasaki S, et al. The association between microalbuminuria and metabolic syndrome in the general population in Japan: the Takahata study. *Intern Med* 2007;46:341-6.
  10. Choi HS, Ryu SH, Lee KB. The relationship of microalbuminuria with metabolic syndrome. *Nephron Clin Pract* 2006;104:85-93.
  11. Klausen KP, Parving HH, Scharling H, et al. The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality. *J Intern Med* 2007;262:470-8.
  12. Lee HO, Bak HJ, Shin JY, et al. Association between Metabolic Syndrome and Microalbuminuria in Korean Adults. *Korean J Fam Med* 2015;36:60-71.
  13. Chen B, Yang D, Chen Y, et al. The prevalence of microalbuminuria and its relationships with the components of metabolic syndrome in the general population of China. *Clin Chim Acta* 2010;411:705-9.
  14. Sheng CS, Hu BC, Fan WX, et al. Microalbuminuria in relation to the metabolic syndrome and its components in a Chinese population. *Diabetol Metab Syndr* 2011;3:6.
  15. Ge Z, Guo X, Chen X, et al. Are Microalbuminuria and Elevated 24 H Urinary Microalbumin Excretion within Normal Range Associated with Metabolic Syndrome in Chinese Adults? *PLoS One* 2015;10:e0138410.
  16. Lee YY, Yang CK, Weng YM, et al. All Components of Metabolic Syndrome Are Associated with Microalbuminuria in a Chinese Population. *PLoS One* 2016;11:e0157303.
  17. Thoenes M, Bramlage P, Khan BV, et al. Albuminuria: pathophysiology, epidemiology and clinical relevance of an emerging marker for cardiovascular disease. *Future Cardiol* 2007;3:519-24.
  18. Crews DC, Boulware LE, Gansevoort RT, et al. Albuminuria: is it time to screen the general population? *Adv Chronic Kidney Dis* 2011;18:249-57.
  19. Xu J, Chen X, Ge Z, et al. Associations of Usual 24-Hour Sodium and Potassium Intakes with Blood Pressure and Risk of Hypertension among Adults in China's Shandong and Jiangsu

1  
2  
3 331 Provinces. *Kidney Blood Press Res* 2017;42:188-200.  
4  
5 332 20. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim  
6  
7 333 statement of the International Diabetes Federation Task Force on Epidemiology and Prevention;  
8  
9 334 National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;  
10 335 International Atherosclerosis Society; and International Association for the Study of Obesity.  
11  
12 336 *Circulation* 2009;120:1640–5.  
13  
14 337 21. Shan Y, Zhang Q, Liu Z, et al. Prevalence and risk factors associated with chronic kidney disease in  
15 338 adults over 40 years: a population study from Central China. *Nephrology (Carlton)*  
16  
17 339 2010;15:354-61.  
18  
19 340 22. Hao G, Wang Z, Zhang L, et al. Prevalence of microalbuminuria among middle-aged population of  
20  
21 341 china: a multiple center cardiovascular epidemiological study. *Angiology* 2015; 66:49-56.  
22 342 23. Chen W, Chen W, Wang H, et al. Prevalence and risk factors associated with chronic kidney  
23  
24 343 disease in an adult population from southern China. *Nephrol Dial Transplant* 2009;24:1205–12.  
25  
26 344 24. Yan L, Ma J, Guo X, et al. Urinary albumin excretion and prevalence of microalbuminuria in a  
27  
28 345 general Chinese population: a cross-sectional study. *BMC Nephrol* 2014;15:165.  
29 346 25. Zhang J, Chen Y, Xu Y, et al. Low-Grade Albuminuria Is Associated with Metabolic Syndrome  
30  
31 347 and Its Components in Middle-Aged and Elderly Chinese Population. *PloS one* 2013; 8: e65597.  
32  
33 348 26. Li MF, Feng QM, Li LX, et al. High-normal urinary albumin-to-creatinine ratio is independently  
34  
35 349 associated with metabolic syndrome in Chinese patients with type 2 diabetes mellitus: A  
36 350 cross-sectional community-based study. *J Diabetes Investig* 2015; 6:354–9.  
37  
38 351 27. Park SY, Park YK, Cho KH, et al. Normal range albuminuria and metabolic syndrome in South  
39  
40 352 Korea: the 2011–2012 Korean National Health and Nutrition Examination Survey. *PloS one*  
41 353 2015;10:e0125615.  
42  
43 354 28. Oh CM, Park SK, Kim HS, et al. High-normal albuminuria predicts metabolic syndrome in  
44  
45 355 middle-aged Korean men: a prospective cohort study. *Maturitas* 2014;77:149-54.  
46 356 29. Li Y, Zhao L, Yu D, et al. Metabolic syndrome prevalence and its risk factors among adults in  
47  
48 357 China: A nationally representative cross-sectional study. *PLoS One* 2018;13:e0199293.  
49  
50 358 30. Murakami K, Sasaki S, Takahashi Y, et al. Sensitivity and specificity of published strategies using  
51  
52 359 urinary creatinine to identify incomplete 24-h urine collection. *Nutrition* 2008; 24:16-22.  
53 360 31. Julibert A, Bibiloni MDM, Tur JA. Dietary fat intake and metabolic syndrome in adults: A  
54  
55 361 systematic review. *Nutr Metab Cardiovasc Dis* 2019; 29:887-905.  
56  
57  
58  
59  
60

**Figure 1.** Prevalence of MAU (panel A) and mean 24-h UAE (panel B) according to the number of MetS components.

For peer review only




Figure 1. Prevalence of MAU (panel A) and mean 24-h UAE (panel B) according to the number of MetS components.



STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract [1]
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found [2]
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported [3–4]
Objectives	3	State specific objectives, including any prespecified hypotheses [4]
Methods		
Study design	4	Present key elements of study design early in the paper [4]
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection [4]
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants [4–5]
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable [5–7]
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group [5–7]
Bias	9	Describe any efforts to address potential sources of bias [7]
Study size	10	Explain how the study size was arrived at [4–5]
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why [5]
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding [7]
		(b) Describe any methods used to examine subgroups and interactions [7]
		(c) Explain how missing data were addressed [5]
		(d) If applicable, describe analytical methods taking account of sampling strategy [N/A]
		(e) Describe any sensitivity analyses [N/A]
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed [8]
		(b) Give reasons for non-participation at each stage [5]
		(c) Consider use of a flow diagram [N/A]
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders [8–9]
		(b) Indicate number of participants with missing data for each variable of interest [8]
Outcome data	15*	Report numbers of outcome events or summary measures [9]
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included [10]
		(b) Report category boundaries when continuous variables were categorized [7,11]

(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period [N/A]		
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses [11]
<b>Discussion</b>		
Key results	18	Summarise key results with reference to study objectives [11-12]
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias [13-14]
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence[13]
Generalisability	21	Discuss the generalisability (external validity) of the study results [13]
<b>Other information</b>		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based [14]

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Association of microalbuminuria and high-normal 24-hour urinary albumin excretion with metabolic syndrome and its components in the general Chinese population: a cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031443.R2
Article Type:	Original research
Date Submitted by the Author:	30-Sep-2019
Complete List of Authors:	Xu, Jianwei; National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Ma, Jixiang; Chinese Center for Disease Control and Prevention Chen, Xiaorong; National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention Yan, Liuxia; National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention Cai, Xiaoning; National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention Guo, Xiaolei; Shandong Center for Disease Control and Prevention Zhang, Yongqing; Jiangsu Center for Disease Control and Prevention Wu, Jing; National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Epidemiology, Public health
Keywords:	Metabolic Syndrome, Microalbuminuria, Urinary Albumin

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**1 Association of microalbuminuria and high-normal 24-hour urinary albumin**  
**2 excretion with metabolic syndrome and its components in the general Chinese**  
**3 population: a cross-sectional study**

**4**  
**5 Jianwei Xu<sup>1</sup>, Jixiang Ma<sup>2</sup>, Xiaorong Chen<sup>1</sup>, Liuxia Yan<sup>1</sup>, Xiaoning Cai<sup>1</sup>, Xiaolei Guo<sup>3</sup>, Yongqing Zhang<sup>4</sup>, Jing**  
**6 Wu<sup>1\*</sup>**

**7** 1 National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center  
**8** for Disease Control and Prevention, Beijing, China, 2 Chinese Center for Disease Control and  
**9** Prevention, Beijing, China, 3 Shandong Center for Disease Control and Prevention, Jinan, China, 4  
**10** Jiangsu Center for Disease Control and Prevention, Nanjing, China

**11**  
**12** Jianwei Xu, xujianwei@ncncd.chinacdc.cn;

**13** Jixiang Ma, majix@163.com;

**14** Xiaorong Chen, chenxiaorong@ncncd.chinacdc.cn;

**15** Liuxia Yan, yanliuxia@ncncd.chinacdc.cn;

**16** Xiaoning Cai, caixiaoning@ncncd.chinacdc.cn;

**17** Xiaolei Guo, guoxiaolei@126.com;

**18** Yongqing Zhang, zyzq6943@163.com;

**19** \*Corresponding author: Jing Wu, E-mail: wujing@ncncd.chinacdc.cn.

## Abstract

**Objective:** Microalbuminuria has been described as a risk factor for metabolic syndrome (MetS). However, the association of MetS components with microalbuminuria and 24-h urinary albumin excretion (UAE) has not been clearly explained in the general Chinese population. We aimed to analyse the associations of microalbuminuria and high-normal 24-h UAE with MetS and its components.

**Design:** Cross-sectional observational study.

**Setting:** Four selected counties/districts in China's Shandong and Jiangsu Provinces.

**Participants:** A total of 2261 participants aged 18-69 years were included in this study. Participants with missing physical examination data or incomplete urine collection were not included in the analysis.

**Results:** The prevalence of microalbuminuria was 9.0%, and the mean 24-h UAE was 18.0 mg/d. The prevalence of microalbuminuria was significantly higher for the MetS, high blood pressure, high triglycerides, low high-density lipoprotein cholesterol (HDL-C) and hyperglycaemia groups but not for the central obesity group. Both microalbuminuria and mean 24-h UAE were significantly increased in association with a number of MetS components. The adjusted prevalence odds ratio (POR) and 95% confidence interval (CI) for MetS with microalbuminuria was 2.95 (2.15 to 4.04) compared to those without microalbuminuria. Microalbuminuria was significantly associated with three components of MetS: high blood pressure, high triglycerides and hyperglycaemia (POR=1.86, 95% CI 1.31 to 2.64; POR=1.80, 95% CI 1.31 to 2.46; and POR=1.84, 95% CI 1.34 to 2.53, respectively). No significant association of microalbuminuria with central obesity or low HDL-C was found. The presence of MetS gradually increased according to the normal-range 24-h UAE quartiles: POR=1.00, POR=1.22, POR=1.14 and POR=2.02, respectively. Hyperglycaemia also increased significantly according to the normal-range 24-h UAE quartiles.

**Conclusions:** Microalbuminuria and elevated 24-h UAE within the normal range were closely associated

1  
2  
3 47 with MetS in the Chinese population, which may provide a basis for the development of early  
4  
5 48 interventions to decrease the effects of MetS.

7  
8 49 **Keywords:** Metabolic Syndrome; Microalbuminuria; Urinary Albumin  
9  
10

11 50

12  
13  
14 51 **Strengths and limitations of this study**  
15

- 16  
17 52 ■ We used 24-h UAE to define microalbuminuria, which is more accurate than most previous studies.  
18  
19 53 ■ This is the largest sample size of the general Chinese population to collected 24-h urine.  
20  
21 54 ■ We explored the association between high-normal 24-h UAE with MetS and its components.  
22  
23 55 ■ A causal relationship between microalbuminuria and MetS cannot be demonstrated in our cross-  
24  
25  
26 56 sectional study.  
27  
28  
29 57

30  
31 58 **INTRODUCTION**  
32  
33

34 59 Microalbuminuria (MAU), defined by abnormally high albumin excretion (30-300 mg/d) in a 24-h urine  
35  
36 60 sample, was significantly associated with chronic kidney disease, cardiovascular disease and progression  
37  
38 61 of end-stage renal disease independent of traditional risk factors.[1-4] Prospective and epidemiologic  
39  
40 62 studies have found that MAU is also a powerful predictor of all-cause and cardiovascular mortality in  
41  
42 63 the general population. [5-6]  
43  
44

45 64 Metabolic syndrome (MetS) is a widely accepted description of a cluster of metabolic abnormalities  
46  
47 65 characterized by obesity, hypertension, dyslipidaemia and hyperglycaemia. [7] Some studies have  
48  
49 66 evaluated the relationship between MetS and MAU as a marker for early-stage chronic kidney disease.[8-  
50  
51 67 11] Significant associations between MetS and MAU have been demonstrated in Japanese, [9] Korean,  
52  
53 68 [10, 12] and Chinese populations. [13-16] However, data concerning the relationship between individual  
54  
55  
56  
57  
58  
59  
60

MetS components and MAU have been inconsistent, and a causal relationship between MAU and MetS remains unclear despite the predictive value MAU showed in the aforementioned studies. Furthermore, the study of the association between normal-range 24-h urinary albumin excretion (UAE) and MetS components has been limited. [15]

The 24-h UAE level is considered the 'gold standard' for defining MAU. [17, 18] However, most of the previous studies of MAU in the Chinese population have used an early morning or random spot urine sample instead of measuring 24-h UAE. Therefore, in this study, we investigated the prevalence of MAU by analysing 24-h UAE and analysed the association of MAU and normal-range 24-h UAE with MetS and its components.

## METHODS

### Study participants

Data were derived from the supplemental baseline survey of the Shandong Ministry of Health Action on Salt Reduction and Hypertension project, which was a cross-sectional survey conducted at four sites in the Shandong and Jiangsu provinces during 2013 and 2014. We used a stratified, multistage sampling method to select the participants. We selected 80 villages or communities from four sites using proportional probability sampling. A random sample of 120 adults aged 18-69 years was drawn from each village or community. A total of 9600 people were selected, and 8995 of these individuals participated in the survey (response rate, 93.7%). A total of 605 replacements were selected from all individuals in the same village or community after excluding the already selected participants. A total of 9600 individuals participated in the survey and physical examination. A random sample of at least 30 adults was drawn among 120 adults from each village or community. A total of 2480 people were selected, and 2295 participated in the survey (response rate, 92.5%). Of the 185 nonresponders, 113 were replaced

1  
2  
3 92 by adults with similar profiles from the same community or village. Finally, a subsample of 2408  
4  
5 93 participants collected a single 24-h urine sample. Participants with the following conditions were not  
6  
7  
8 94 required to provide urine samples: (1) patients who had difficulty collecting a urine sample; (2) patients  
9  
10 95 with an acute or chronic urinary infection; (3) women who were pregnant, breastfeeding, or actively  
11  
12 96 menstruating; and (4) patients with severe vomiting or diarrhoea. We excluded 3 subjects with missing  
13  
14  
15 97 data from their physical examination or blood samples and 127 participants with incomplete 24-h urine  
16  
17 98 collection. For the purpose of the present study on microalbuminuria, we also excluded 17 subjects with  
18  
19 99 macroalbuminuria or a 24-h UAE >300 mg/d. Therefore, a total of 2261 participants were included in  
20  
21  
22 100 this study.

23  
24 101 Our study was approved by the ethics committee of the National Center for Chronic and  
25  
26 102 Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention  
27  
28  
29 103 (201311). Written informed consent was obtained from all participants.

30  
31 104 **Demographic, anthropometrical and biochemical data collection**

32  
33  
34 105 A face-to-face interview was conducted by local trained health professionals using a standard  
35  
36 106 questionnaire. Relevant variables included age, sex, educational level, smoking status, alcohol intake,  
37  
38  
39 107 regular exercise and previous diagnosis and treatment of hypertension and diabetes. During the physical  
40  
41 108 examination, height, weight, waist circumference (WC) and blood pressure (BP) were measured by  
42  
43 109 trained researchers using standardized protocols and techniques. Weight and height were measured with  
44  
45 110 participants dressed in light, indoor clothing without shoes using standardized techniques and calibrated  
46  
47  
48 111 equipment. Waist circumference was measured at the narrowest point between the lower border of the  
49  
50 112 rib cage and the iliac crest. The body mass index (BMI) was calculated as the weight in kilograms divided  
51  
52 113 by the height in metres squared (kg/m<sup>2</sup>). Blood pressure was measured three times by an electronic  
53  
54  
55 114 sphygmomanometer (HEM-7071, Omron Corporation, Japan), and the final blood pressure was obtained



by averaging the three measurements.

Fasting blood samples collected from each participant were processed and shipped in cold storage to a certified laboratory (ADICON Clinical Laboratory Inc., Jinan, China). Fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were measured. Plasma glucose was measured using a modified hexokinase enzymatic method. Serum cholesterol and triglyceride levels were analysed enzymatically using commercially available reagents.

## 24-h Urine collection and analysis

Eligible participants were instructed not to change their dietary or lifestyle habits. We provided a standard plastic container for each participant to collect a 24-h urine sample. Trained researchers gave each participant both written and verbal instructions on how to collect a 24-h urine sample. Health professionals carefully explained to the subjects the purpose of the 24-h urine collection and asked the subjects to correctly repeat the information. The exact 24-h urine collection time, including starting and ending times, was recorded by the supervising health professional. The total volume of the collection was measured by a laboratory technician, and urine aliquots were frozen at  $-20^{\circ}\text{C}$  for approximately 30 days and shipped to the ADICON Clinical Laboratory in Jinan. Urinary creatinine was measured by the picric acid method. UAE was measured with an immunonephelometric method using the Olympus AU640 Analyser, for which the coefficient of variation was 3.0%. Either a 24-h urinary volume less than 500 ml or a 24-h urinary creatinine volume that was  $\pm 2$  standard deviations (SD) outside of the sex-specific mean, 0.98 to 16.17 mmol/l for men and 0.93 to 13.60 mmol/l for women, was defined as an incomplete urine collection. [19]

## Definition of metabolic syndrome

We adopted the harmonized criteria of MetS, which defines MetS as the presence of  $\geq 3$  of the following

1  
2  
3 138 risk factors [20]: central obesity defined as a WC  $\geq 90$  cm in men and  $\geq 80$  cm in women; high BP defined  
4  
5  
6 139 as a systolic blood pressure (SBP)  $\geq 130$  mmHg, a diastolic blood pressure (DBP)  $\geq 85$  mmHg or treatment  
7  
8 140 with an antihypertensive medication; high triglycerides defined as a fasting plasma TC level  $\geq 1.7$  mmol/l  
9  
10  
11 141 or drug treatment for increased TC; low HDL-C defined as HDL-C  $< 1.0$  mmol/l in men and  $< 1.3$  mmol/l  
12  
13 142 in women or drug treatment for low HDL-C; and hyperglycaemia defined as a FBG level  $\geq 5.6$  mmol/l  
14  
15 143 or drug treatment for increased FBG.  
16  
17

18 144 **Statistical analysis**

19  
20  
21 145 Continuous variables are presented as the mean (SD), and categorical variables are presented as  
22  
23 146 percentages. According to their quartiles of 24-h UAE in a normal range (n=2058), study subjects were  
24  
25 147 divided into four groups: Q1, 0–9.38 mg/d; Q2, 9.39–11.96 mg/d; Q3, 11.97–15.46 mg/d; and Q4, 15.47–  
26  
27 148 29.99 mg/d.  
28  
29

30 149 We performed logistic regression analyses to study the association of MAU and 24-h UAE with  
31  
32 150 MetS and its components while controlling for covariates including sociodemographic factors (age, sex,  
33  
34 151 education level) and lifestyle factors (regular exercise, alcohol intake and smoking). Participants who did  
35  
36  
37 152 not have microalbuminuria or who were in the Q1 group were used as a reference group to estimate the  
38  
39 153 prevalence odds ratios (PORs) and 95% confidence intervals (CIs). Tests of linear trends across  
40  
41 154 increasing quartiles of 24-h UAE were conducted by treating the medians of the average 24-h UAE as a  
42  
43  
44 155 continuous variable in the logistic regression models. Statistical analyses were performed with SAS 9.3  
45  
46 156 (SAS Institute Inc.). The tests performed were two-sided, and a *p*-value  $< 0.05$  was considered statistically  
47  
48 157 significant.  
49  
50

51 158 **Patient and public involvement**

52  
53  
54 159 Patients and the public were not involved in the design or planning of the study.  
55  
56  
57  
58  
59  
60

## RESULTS

### Characteristics of subjects

Among the 2261 participants, the prevalence of MAU was 9.0% (203), and the prevalence was not significantly different between males and females (8.8% vs. 9.1%,  $p=0.08$ ). The mean 24-h UAE was 18.0 mg/d. The population characteristics are summarized according to microalbuminuria and normal-range 24-h UAE quartiles in Table 1. Compared to those without MAU, participants with MAU were more likely to have higher WC, BMI, SBP, DBP, FBG and TG. Similarly, these variables were also significantly different among increasing quartiles of 24-h UAE.

Table 1. General characteristics of the study participants

	Normal range 24-h UAE (mg/d)				<i>p</i> -value	Microalbuminuria		<i>p</i> -value
	Q1	Q2	Q3	Q4		No	Yes	
Number of subjects	515	515	516	512		2058	203	
Age (years)	41.7(13.5)	42.5(13.5)	41.8(13.5)	42.5(13.3)	0.67	42.1(13.5)	41.4(13.5)	0.48
Men (%)	51.8	48.2	50.8	48.4	0.57	49.8	48.8	0.78
BMI (kg/cm <sup>2</sup> )	24.4(3.6)	24.6(3.6)	24.7(3.9)	25.5(3.9)	<0.001	24.8(3.8)	26.0(4.5)	<0.001
WC (cm)	82.3(9.1)	82.4(9.6)	82.7(9.9)	84.8(10.5)	<0.001	83.0(9.8)	85.8(12.5)	<0.001
SBP (mmHg)	129.5(19.4)	130.7(18.5)	129.8(18.7)	133.1(20.7)	0.0111	130.8(19.4)	136.1(23.3)	<0.001
DBP (mmHg)	81.8(11.4)	83.1(10.8)	82.5(11.4)	84.9(12.2)	<0.001	83.1(11.5)	87.9(14.4)	<0.001
High-school (%)	24.1	21.9	23.1	25.4	0.61	23.6	26.6	0.34
Smoking (%)	30.1	29.1	29.1	27.3	0.80	28.9	33.0	0.22
Alcohol (%)	23.7	27.6	26.2	27.3	0.47	26.2	27.1	0.78
Regular exercise (%)	17.3	16.7	22.3	22.3	0.03	19.6	30.5	<0.001
FBG (mmol/L)	5.6(1.1)	5.6(1.0)	5.7(1.1)	6.0(1.7)	<0.001	5.7(1.3)	6.5(2.4)	<0.001
TC (mmol/L)	4.7(0.9)	4.8(0.9)	4.8(0.9)	4.9(1.0)	0.0281	4.8(0.9)	5.1(1.0)	<0.001
HDL (mmol/L)	1.3(0.3)	1.3(0.3)	1.3(0.3)	1.2(0.3)	0.0203	1.3(0.3)	1.2(0.3)	0.03
LDL (mmol/L)	2.4(0.7)	2.4(0.6)	2.5(0.7)	2.5(0.7)	0.0186	2.4(0.7)	2.5(0.7)	0.06
TG (mmol/L)	1.4(1.2)	1.4(1.3)	1.5(1.4)	1.8(2.1)	<0.001	1.6(1.6)	2.3(2.4)	<0.001
Creatinine (mmol/d)	6.0(2.2)	7.4(2.6)	8.0(3.2)	8.6(3.1)	<0.001	7.5(3.0)	8.8(3.1)	<0.001
24-h UAE (mg/d)	7.7(1.2)	10.7(0.8)	13.5(1.0)	20.1(3.7)	<0.001	13.0(5.0)	68.8(50.4)	<0.001

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**MAU and 24-h UAE by the number of MetS components**

The prevalence of MAU in individuals with MetS and its components is shown in Table 2. The prevalence of MAU was significantly higher in the MetS, high BP, high triglycerides and hyperglycaemia groups. The prevalence of MAU among subjects with 0 (n=342), 1 (n=632), 2 (n=632), 3 (n=433), and 4 or 5 (n=222) components of MetS was 5.0, 5.5, 8.2, 14.5 and 16.2%, respectively. The corresponding mean 24-h UAE measurements were 14.5, 15.1, 17.9, 22.7 and 22.8 mg/d, respectively. Overall, both the prevalence of MAU and the mean 24-h UAE were significantly elevated according to the number of MetS components with all *p*-values <0.001 (Fig 1).

Table 2. Association of microalbuminuria with MetS and its components

Components	Microalbuminuria (%)		<i>p</i> -value
	No (n=2058)	Yes (n=203)	
Central obesity			
No	91.49	8.51	0.1982
Yes	89.76	10.24	
High BP			
No	93.52	6.48	<0.001
Yes	88.85	11.15	
High triglycerides			
No	93.11	6.89	<0.001
Yes	86.18	13.82	
Low HDL-C			
No	91.81	8.19	0.0249
Yes	88.72	11.28	
Hyperglycaemia			
No	93.94	6.06	<0.0001
Yes	87.78	12.22	
Metabolic syndrome			

No	93.52	6.48	<0.0001
Yes	84.89	15.11	

## Association between MAU and MetS components

The associations between MAU and the components of MetS are shown in Table 3. Compared with participants without microalbuminuria, the age- and sex-adjusted POR (95% CI) for MetS with microalbuminuria was 2.93 (2.15 to 4.00), and the multivariate-adjusted POR (95% CI) was 2.95 (2.15 to 4.04). For MetS components, in both the age- and sex-adjusted and multivariate-adjusted models, MAU was strongly associated with high BP, high triglycerides and hyperglycaemia. However, no significant association between MAU and central obesity or low HDL-C was found.

Table 3. Relationship between MAU and metabolic syndrome components

	No. of cases	Without microalbuminuria	Microalbuminuria	
			Model 1 <sup>a</sup>	Model 2 <sup>b</sup>
Metabolic syndrome	655	1.00	2.93 (2.15 to 4.00)	2.95 (2.15 to 4.04)
Central obesity	615	1.00	1.40 (0.92 to 2.13)	1.02 (0.65 to 1.60)
High BP	1211	1.00	2.20 (1.57 to 3.09)	1.86 (1.31 to 2.64)
High triglycerides	680	1.00	2.21 (1.65 to 2.97)	1.80 (1.31 to 2.46)
Low HDL-C	576	1.00	1.71 (1.13 to 2.60)	1.32 (0.85 to 2.04)
Hyperglycaemia	1072	1.00	2.28 (1.68 to 3.11)	1.84 (1.34 to 2.53)

<sup>a</sup>Model 1: adjusted for age and sex;

<sup>b</sup>Model 2: adjusted for age, sex, education attainment, regular exercise, alcohol consumption, smoking and for the other components of MetS (except for analyses of MetS).

## Associations between high-normal 24-h UAE and MetS

1  
2  
3 194 Table 4 shows that the odds of MetS gradually increased according to the normal-range 24-h UAE  
4  
5  
6 195 quartiles. The multivariate-adjusted PORs of MetS were 1.22, 1.14 and 2.02 for 24-h UAE quartiles 2, 3  
7  
8 196 and 4, respectively, compared with the lowest quartile ( $p<0.0001$ ). Furthermore, compared to the lowest  
9  
10 197 24-h UAE quartile, the multivariate-adjusted POR of the highest quartile was 1.52 for hyperglycaemia  
11  
12 198 ( $p<0.01$ ). However, no significant associations between normal-range 24-h UAE and the other  
13  
14  
15 199 components of MetS were found.

16  
17  
18 200 Table 4. Normal-range 24-h UAE quartiles associated with MetS and its components

		Prevalence Odds Ratio (95% CI)				<i>p</i> -Value
		Q1	Q2	Q3	Q4	
Metabolic syndrome						
	Model 1 <sup>a</sup>	1.00	1.24 (0.91 to 1.67)	1.15 (0.84 to 1.56)	2.03 (1.51 to 2.72)	<0.0001
	Model 2 <sup>b</sup>	1.00	1.22 (0.90 to 1.65)	1.14 (0.84 to 1.55)	2.02 (1.51 to 2.72)	<0.0001
Central obesity						
	Model 1 <sup>a</sup>	1.00	1.35 (0.94 to 1.94)	1.07 (0.75 to 1.55)	1.72 (1.19 to 2.48)	0.0154
	Model 2 <sup>b</sup>	1.00	1.29 (0.89 to 1.88)	1.07 (0.73 to 1.58)	1.53 (1.04 to 2.25)	0.1221
High BP						
	Model 1 <sup>a</sup>	1.00	1.18 (0.90 to 1.54)	0.99 (0.75 to 1.29)	1.43 (1.09 to 1.87)	0.0253
	Model 2 <sup>b</sup>	1.00	1.12 (0.85 to 1.48)	0.93 (0.71 to 1.23)	1.24 (0.94 to 1.64)	0.1957
High triglycerides						
	Model 1 <sup>a</sup>	1.00	0.96 (0.72 to 1.26)	1.00 (0.76 to 1.32)	1.43 (1.09 to 1.87)	0.0092
	Model 2 <sup>b</sup>	1.00	0.84 (0.63 to 1.13)	0.93(0.69 to 1.24)	1.18 (0.89 to 1.56)	0.1242
Low HDL-C						
	Model 1 <sup>a</sup>	1.00	1.37 (0.96 to 1.93)	1.28 (0.90 to 1.81)	1.55 (1.09 to 2.20)	0.0953
	Model 2 <sup>b</sup>	1.00	1.34 (0.93 to 1.94)	1.26 (0.87 to 1.83)	1.29 (0.89 to 1.87)	0.4045
Hyperglycaemia						
	Model 1 <sup>a</sup>	1.00	1.12 (0.87 to 1.44)	1.37 (1.07 to 1.77)	1.72 (1.33 to 2.21)	0.0001
	Model 2 <sup>b</sup>	1.00	1.09 (0.84 to 1.41)	1.34 (1.03 to 1.74)	1.52 (1.17 to 1.98)	0.0055

55 201 <sup>a</sup>Model 1: adjusted for age and sex;

<sup>b</sup>Model 2: adjusted for age, sex, education attainment, regular exercise, alcohol consumption, smoking and for the other components of MetS (except for the analyses of MetS).

## DISCUSSION

Our study showed that the prevalence of MAU was 9.0% in the study population and was much more prevalent in persons with MetS (15.1%) in particular. The prevalence of MAU in our study was moderate compared with that in other studies in China (4.1% to 15%). [13-14, 21-24] This varied prevalence observed in the Chinese population may be associated with different age distributions, regions, and methods of defining MAU.

In the current study, the prevalence of MAU was consistently higher in persons with MetS than in those without MetS. The prevalence of MAU increased significantly with increasing numbers of MetS components after the subjects were divided by the number of MetS components. The same results were obtained in previous studies. [12-15, 25-26] This finding indicates that a large number of participants with MAU are easily overlooked in routine health examinations that do not include MAU measurements. This finding also suggests that intervention for MetS should be initiated at the earliest stage of renal injury.

Furthermore, our study showed that MAU was significantly associated with MetS and its components, apart from central obesity and low HDL-C. Many epidemiologic studies have suggested an independent association between MAU and MetS. However, findings on the associations between various components of MetS and MAU are controversial. Blood pressure and fasting glucose were consistently found to be two main risk factors associated with MAU, which was also clearly shown in our study. However, the associations between MAU and abdominal obesity, HDL and triglycerides were inconsistent in previous studies. [8, 9, 16] Thus far, two studies have reported an association between

1  
2  
3 226 MAU and risk of MetS, with ORs (95% CI) of 5.13 (1.96 to 13.45) and 2.71 (1.69 to 4.36), [14, 15]  
4  
5  
6 227 which is consistent with our finding.

7  
8 228 Our study further showed that the prevalence of MetS gradually increased with increasing normal-  
9  
10 229 range 24-h UAE quartiles, which is consistent with previous studies. [15, 26-28] Thus far, only one  
11  
12 230 prospective cohort study reported hazard ratios with 95% CIs for MetS: 1.57 (1.14 to 2.18) for the three  
13  
14  
15 231 highest albumin-to-creatinine ratio quartiles compared to the lowest one. [28] However, the association  
16  
17 232 between the components of MetS and high-normal 24-h UAE were not exactly the same. Ge et al.  
18  
19 233 reported that the relationship between 24-h UAE within the normal range and central obesity, elevated  
20  
21  
22 234 blood pressure and elevated triglycerides was significant. [15] Another study also found that the  
23  
24 235 association between low-grade albuminuria and the components of MetS, except for low HDL-C, was  
25  
26 236 significant. [25] In our study, a relationship between high-normal 24-h UAE and hyperglycaemia in the  
27  
28  
29 237 general Chinese population was found. This association persisted after adjustment for multiple risk  
30  
31 238 factors.

32  
33 239 In our study, we found that not only MAU but also elevated 24-h UAE within the normal range had  
34  
35 240 a significant relationship with an increased risk of MetS in Chinese adults. The magnitude of this  
36  
37  
38 241 association persisted after controlling for traditional risk factors. Our finding has important public health  
39  
40 242 implications for preventing MetS. [15] The prevalence of MetS in China was 24.2% [29] and is becoming  
41  
42 243 a serious public health problem in China. Our findings demonstrated that reducing 24 h UAE even within  
43  
44  
45 244 the normal range should be an important priority for reducing the effects of MetS. Our study suggested  
46  
47 245 that clinicians should carefully evaluate the risk of MetS in individuals with normal-range UAE. Annual  
48  
49 246 MAU screening in the MetS population should be an essential part of our preventive medicine efforts.  
50  
51  
52 247 Policy makers should support such screening as part of the universal coverage policy programmes.



Our study had strengths. First, we used 24-h UAE to define microalbuminuria in a relatively large sample population, which was more accurate than most previous studies in the general Chinese population. Furthermore, this population-based epidemiologic study found an association between high-normal 24-h UAE and MetS, which is different from most previous studies in China. In addition, our study rigorously used standardized methods and quality control for data collection. However, our study had several limitations. First, due to investigative convenience, we did not use an objective biomarker, such as para-aminobenzoic acid, to assess complete 24-h urine. [30] We assessed the completeness by measuring urinary volume and creatinine concentration in the present study. Second, we did not evaluate the renal function of the subjects, which may have caused some bias in the results. Third, although multiple covariates were included in the adjustment, some potential confounding factors, such as dietary intake [31] and other medications could not be ruled out. Finally, because this study had a cross-sectional design, it was difficult to interpret a causal association between MAU and 24-h UAE with MetS and its components. Therefore, future prospective studies are recommended to confirm our findings.

## CONCLUSIONS

Our study confirmed that both MAU and high-normal 24-h UAE were strong risk factors for MetS in the general Chinese population. The assessment of these risk factors can result in an opportunity for early intervention to decrease the effects of MetS in China.

**Acknowledgements** Special thanks to Prof. Jixiang Ma for his great contribution to the project initiation. We would like to express our sincere appreciation to all staff for performing the field work. We are also grateful to all the study participants.

**Contributions** JM, XChen, JW designed the study and supervised data collection. JX, LY, XCai, XG, and YZ participated in field work and data collection. JX and LY analysed the data. JX wrote the

1  
2  
3 271 manuscript to which all the authors contributed. JM and JW critically revised the manuscript for  
4  
5 272 important intellectual content. All the authors reviewed and approved the final manuscript.  
6  
7  
8 273 **Funding** The survey was supported by Shandong-Ministry of Health Action on Salt Reduction and  
9  
10 274 Hypertension (No. 2013) and the Young Scholar Scientific Research Foundation of the Chinese Center  
11  
12 275 for Disease Control and Prevention (No. 2018A203).  
13  
14  
15 276 **Competing interests** None declared.  
16  
17 277 **Ethics approval** The survey was approved by the Ethics Committee of the National Center for Chronic  
18  
19 278 and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and  
20  
21  
22 279 Prevention.  
23  
24 280 **Provenance and peer review** Not commissioned; externally peer reviewed.  
25  
26 281 **Data sharing statement** A de-identified minimal data set that underlies the findings and conclusions  
27  
28 282 described in the manuscript can be shared upon request by the editors to verify the reported study findings.  
29  
30  
31 283  
32  
33

## 34 284 **References**

- 35  
36  
37 285 1. Chronic Kidney Disease Prognosis C, Matsushita K, van der Velde M, et al. Association of estimated  
38 286 glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general  
39  
40 287 population cohorts: a collaborative meta-analysis. *Lancet* 2010;375:2073-81.  
41  
42 288 2. Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher  
43 289 albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general  
44  
45 290 and high-risk population cohorts. *Kidney Int* 2011;80:93-104.  
46  
47 291 3. Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and higher  
48  
49 292 albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis  
50  
51 293 of kidney disease population cohorts. *Kidney Int* 2011;79:1331-40.  
52 294 4. Van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher  
53  
54 295 albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis  
55  
56 296 of high-risk population cohorts. *Kidney Int* 2011;79:1341-52.  
57  
58  
59  
60

5. Chen YY, Li YY, Lu YH, Albuminuria independently predicts cardiovascular and all-cause mortality in a middle-aged and elderly Chinese population. *Scand J Clin Lab Invest* 2012;72:281-6.
6. Yuyun MF, Khaw KT, Luben R, et al. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. *Int J Epidemiol* 2004;33:189-98.
7. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med* 2006;23:469-80.
8. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. *Am J Hypertens* 2003;16:952-8.
9. Hao Z, Konta T, Takasaki S, et al. The association between microalbuminuria and metabolic syndrome in the general population in Japan: the Takahata study. *Intern Med* 2007;46:341-6.
10. Choi HS, Ryu SH, Lee KB. The relationship of microalbuminuria with metabolic syndrome. *Nephron Clin Pract* 2006;104:85-93.
11. Klausen KP, Parving HH, Scharling H, et al. The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality. *J Intern Med* 2007;262:470-8.
12. Lee HO, Bak HJ, Shin JY, et al. Association between Metabolic Syndrome and Microalbuminuria in Korean Adults. *Korean J Fam Med* 2015;36:60-71.
13. Chen B, Yang D, Chen Y, et al. The prevalence of microalbuminuria and its relationships with the components of metabolic syndrome in the general population of China. *Clin Chim Acta* 2010;411:705-9.
14. Sheng CS, Hu BC, Fan WX, et al. Microalbuminuria in relation to the metabolic syndrome and its components in a Chinese population. *Diabetol Metab Syndr* 2011;3:6.
15. Ge Z, Guo X, Chen X, et al. Are Microalbuminuria and Elevated 24 H Urinary Microalbumin Excretion within Normal Range Associated with Metabolic Syndrome in Chinese Adults? *PLoS One* 2015;10:e0138410.
16. Lee YY, Yang CK, Weng YM, et al. All Components of Metabolic Syndrome Are Associated with Microalbuminuria in a Chinese Population. *PLoS One* 2016;11:e0157303.
17. Thoenes M, Bramlage P, Khan BV, et al. Albuminuria: pathophysiology, epidemiology and clinical relevance of an emerging marker for cardiovascular disease. *Future Cardiol* 2007;3:519-24.
18. Crews DC, Boulware LE, Gansevoort RT, et al. Albuminuria: is it time to screen the general

1  
2  
3 328 population? *Adv Chronic Kidney Dis* 2011;18:249-57.  
4  
5 329 19. Xu J, Chen X, Ge Z, et al. Associations of Usual 24-Hour Sodium and Potassium Intakes with Blood  
6  
7 330 Pressure and Risk of Hypertension among Adults in China's Shandong and Jiangsu Provinces.  
8  
9 331 *Kidney Blood Press Res* 2017;42:188-200.  
10 332 20. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim  
11  
12 333 statement of the International Diabetes Federation Task Force on Epidemiology and Prevention;  
13  
14 334 National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;  
15 335 International Atherosclerosis Society; and International Association for the Study of Obesity.  
16  
17 336 *Circulation* 2009;120:1640-5.  
18  
19 337 21. Shan Y, Zhang Q, Liu Z, et al. Prevalence and risk factors associated with chronic kidney disease in  
20  
21 338 adults over 40 years: a population study from Central China. *Nephrology (Carlton)* 2010;15:354-61.  
22 339 22. Hao G, Wang Z, Zhang L, et al. Prevalence of microalbuminuria among middle-aged population of  
23  
24 340 china: a multiple center cardiovascular epidemiological study. *Angiology* 2015; 66:49-56.  
25  
26 341 23. Chen W, Chen W, Wang H, et al. Prevalence and risk factors associated with chronic kidney disease  
27  
28 342 in an adult population from southern China. *Nephrol Dial Transplant* 2009;24:1205-12.  
29 343 24. Yan L, Ma J, Guo X, et al. Urinary albumin excretion and prevalence of microalbuminuria in a  
30  
31 344 general Chinese population: a cross-sectional study. *BMC Nephrol* 2014;15:165.  
32  
33 345 25. Zhang J, Chen Y, Xu Y, et al. Low-Grade Albuminuria Is Associated with Metabolic Syndrome and  
34 346 Its Components in Middle-Aged and Elderly Chinese Population. *PloS one* 2013; 8: e65597.  
35  
36 347 26. Li MF, Feng QM, Li LX, et al. High-normal urinary albumin-to-creatinine ratio is independently  
37  
38 348 associated with metabolic syndrome in Chinese patients with type 2 diabetes mellitus: A cross-  
39  
40 349 sectional community-based study. *J Diabetes Investig* 2015; 6:354-9.  
41 350 27. Park SY, Park YK, Cho KH, et al. Normal range albuminuria and metabolic syndrome in South Korea:  
42  
43 351 the 2011-2012 Korean National Health and Nutrition Examination Survey. *PloS one*  
44  
45 352 2015;10:e0125615.  
46 353 28. Oh CM, Park SK, Kim HS, et al. High-normal albuminuria predicts metabolic syndrome in middle-  
47  
48 354 aged Korean men: a prospective cohort study. *Maturitas* 2014;77:149-54.  
49  
50 355 29. Li Y, Zhao L, Yu D, et al. Metabolic syndrome prevalence and its risk factors among adults in China:  
51  
52 356 A nationally representative cross-sectional study. *PLoS One* 2018;13:e0199293.  
53 357 30. Murakami K, Sasaki S, Takahashi Y, et al. Sensitivity and specificity of published strategies using  
54  
55 358 urinary creatinine to identify incomplete 24-h urine collection. *Nutrition* 2008; 24:16-22.  
56  
57  
58  
59  
60

31. Julibert A, Bibiloni MDM, Tur JA. Dietary fat intake and metabolic syndrome in adults: A systematic review. *Nutr Metab Cardiovasc Dis* 2019; 29:887-905.

**Figure 1.** Prevalence of MAU (panel A) and mean 24-h UAE (panel B) according to the number of MetS components.

For peer review only




Figure 1. Prevalence of MAU (panel A) and mean 24-h UAE (panel B) according to the number of MetS components.

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract [1] (b) Provide in the abstract an informative and balanced summary of what was done and what was found [2]
<b>Introduction</b>		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported [3-4]
Objectives	3	State specific objectives, including any prespecified hypotheses [4]
<b>Methods</b>		
Study design	4	Present key elements of study design early in the paper [4]
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection [4]
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants [4-5]
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable [5-7]
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group [5-7]
Bias	9	Describe any efforts to address potential sources of bias [7]
Study size	10	Explain how the study size was arrived at [4-5]
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why [5]
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding [7] (b) Describe any methods used to examine subgroups and interactions [7] (c) Explain how missing data were addressed [5] (d) If applicable, describe analytical methods taking account of sampling strategy [N/A] (e) Describe any sensitivity analyses [N/A]
<b>Results</b>		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed [8] (b) Give reasons for non-participation at each stage [5] (c) Consider use of a flow diagram [N/A]
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders [8-9] (b) Indicate number of participants with missing data for each variable of interest [8]
Outcome data	15*	Report numbers of outcome events or summary measures [9]
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included [10] (b) Report category boundaries when continuous variables were categorized [7,11]

(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period [N/A]		
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses [11]
<b>Discussion</b>		
Key results	18	Summarise key results with reference to study objectives [11-12]
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias [13-14]
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence[13]
Generalisability	21	Discuss the generalisability (external validity) of the study results [13]
<b>Other information</b>		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based [14]

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).